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ABSTRACT 
 
 Restenosis is one of the major adverse outcomes of Percutaneous Coronary 
Intervention (PCI).  Previous studies have shown conflicting reports for homocysteine as 
a predictor of restenosis following PCI.  The conflicting reports may be due to oxidative 
factors (stimulation of polymorphonuclear leukocyte [PMNL]-induced reactive oxygen 
species generation, xanthine- xanthine oxidase, and arachidonic acid metabolism) other 
than homocysteine which could cause endothelial cell dysfunction leading to restenosis.  
Malondialdehyde (MDA), a lipid peroxidation product, is a marker for oxidative stress 
and is related to all oxidative factors.  Therefore, it is possible that serum MDA may be a 
better predictor of restenosis than plasma homocysteine.  The purpose of this study is to 
determine whether or not the pre-procedural serum MDA and plasma homocysteine 
levels are elevated in patients who develop restenosis post PCI. 
 The study included fifty-one patients undergoing elective PCI who consented to 
participate in a protocol that was approved by the Ethics Committee of the University of 
Saskatchewan.  Homocysteine and malondialdehyde were measured in the plasma and 
serum respectively.  Blood samples were collected pre-procedural, 0 time, 8 hours, 24 
hours, and 6 months post-procedure.  Exercise tolerance tests were performed at two 
weeks, and six months post-procedure to determine if there was any evidence of 
restenosis. 
 The results of the study showed that pre-procedural values of plasma 
homocysteine in the restenosis and non-restenosis groups were 10.37 ± 0.46 and 10.73 ± 
0.49 respectively.  These values were not significantly different (p=0.60) between the 
groups.  The pre-procedural levels of plasma homocysteine were not significantly 
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different (p=0.08) from the post-PCI values of those patients who did not develop 
restenosis at the 6-month time interval.   However, the pre-procedural levels of plasma 
homocysteine were significantly different from the post-PCI values of those patients in 
the restenosis group at the 24hr (p=0.04) and 6-month (p=0.002) time intervals.  In the 
restenosis group there was a significant increase (24%) after six months in the values of 
homocysteine from the pre-procedural levels.  Thus, this indicates that restenosis is 
associated with higher post-PCI levels of homocysteine. 
 The pre-procedural levels of serum MDA in the restenosis and non-restenosis 
groups were 0.124± 0.16 and 0.147± 0.02 respectively.  There was no significant 
difference (p=0.60) between the two groups. There was also no significant difference 
(p=0.053) between the pre-procedural values and the 6-month post-PCI values in those 
patients who did not develop restenosis.  However, there was a significant difference 
(p=0.001) between the pre-procedural values and the 6-month post-PCI values in those 
patients who developed restenosis. The levels of serum MDA in patients with restenosis 
at 6-months increased by 109% and were significantly different (p=0.001) in the 
restenosis group.  
 The results suggest that pre-procedural levels of plasma homocysteine and serum 
MDA were not predictors of restenosis following PCI.  However, the post-PCI six-
month levels of both homocysteine and MDA are predictors of restenosis.  Moreover, 
the post-PCI levels of MDA were better predictors of restenosis than the post-PCI levels 
of homocysteine because the increase in MDA levels were greater at six months than the 
rise in homocysteine levels at the same time interval. 
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1.0 REVIEW OF THE LITERATURE 
1.1 INTRODUCTION 
Myocardial infarction (MI) consequent to atherosclerosis of a coronary  
 artery is one of the principal causes of death in western civilization.  As outlined by 
Prasad (1999) within this high-risk population, hyperhomocysteinemia, smoking, 
hypercholesterolemia, diabetes and hypertension are independent risk factors for 
coronary artery disease (CAD).  Percutaneous Coronary Intervention (PCI) is one of the 
procedures performed to reduce the ischemic effects of CAD.  Although much progress 
has been made in the field of interventional cardiology, restenosis remains as one of the 
adverse outcomes of PCI.  The relationship between plasma levels of homocysteine and 
restenosis in patients with CAD who have undergone PCI remains unsolved. 
Kojoglanian et al. (2003) demonstrated that elevated levels of homocysteine strongly 
correlate with increased risk for restenosis.  However, Ambrosi (2003) showed that 
hyperhomocysteinemia is probably a weak risk factor for the development of restenosis.  
This discrepancy may be due to factors other than homocysteine, which can generate 
oxygen radicals during CAD. Polymorphonuclear leukocytes (PMNLs), xanthine-
xanthine oxidase, arachidonic acid metabolism, homocysteine and cytokines generate 
oxygen radicals (ORs), which induce oxidative stress in patients with CAD (Chambers 
et al. 1985; Kapoor and Prasad, 1996; Prasad et al. 1993).  Furthermore, ORs cause 
endothelial damage by attacking polyunsaturated fatty acids with the formation of lipid 
hydroperoxides and conjugated dienes (Rumley and Paterson, 1998).  Malondialdehyde 
(MDA) is a lipid peroxidation product, which provides an indirect measure of oxidative 
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stress.  The present investigation was undertaken to determine: (1) if serum MDA and 
plasma homocysteine are predictors of post-PCI restenosis; and (2) if serum MDA is a 
better predictor of post-PCI restenosis than homocysteine.        
1.1.1 Atherosclerosis and Coronary Artery Disease 
 The term atherosclerosis is derived from the Greek “athero” (gruel or porridge) 
and “sclerosis” (hardening).   It is a chronic inflammatory disease of the arteries in 
which macrophages and oxidized lipids are the primary agents, resulting in intimal fibro-
fatty plaque formation and progression.  Atherosclerosis begins in childhood and slowly 
progresses over many years before it manifests itself with clinical symptoms (Ross and 
Glomset, 1976).  The arteries generally affected by atherosclerosis are the thoracic aorta, 
coronary, internal carotids, femoral, basilar, vertebral, and circle of Willis.  Myocardial 
infarction and stroke are two of the major clinical consequences of diminished or halted 
blood flow created by atherosclerosis (Ross and Glomset, 1976). 
1.1.1.1 Epidemiology of Atherosclerosis 
In North America, atherosclerosis continues to be one of the prominent causes of 
morbidity and mortality. “The incidence of disease related to atherosclerosis is as 
follows: ischemic heart disease (IHD), 7 million; peripheral vascular disease, 3 million; 
and stroke, 0.75 million per year”, as described by Prasad (2003a).  It is a ubiquitous 
disease among developed countries and has geographical variations.  For instance, 
coronary artery disease in North America is six times higher than in Japan (Ross, 1986). 
1.1.1.2 Pathology of Atherosclerosis 
Intimal focal lesions of atherosclerosis are visible fatty streaks with raised yellow 
areas that are slender and longitudinally oriented.  They are made up of lipid laden foam 
cells, which are macrophages and or smooth muscle cells.  Fibrous plaques lesions are 
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raised off white lesions with three layers.  The first layer is a fibrous cap consisting of 
smooth muscle cells, and leukocytes, along with dense connective tissue. This 
connective tissue consists of a basement membrane, collagen fibrils, proteoglycans, and 
elastin.  The second layer is a cellular region under and adjacent to the fibrous cap. This 
layer is composed of a combination of smooth muscle cells, T lymphocytes and 
macrophages.  The final lower necrotic layer is composed of immense foam cells, 
cellular debris, lipids, and calcium crystals (Duff and McMillian, 1951).  However, most 
patients with atherosclerosis present with a combination and/ or variations of each of 
these characteristics.  The organization of lipid and connective tissue in these lesions 
determines whether or not they are complicated lesions that are stable or unstable with 
the possibility of rupture and/ or thrombosis as outlined by Prasad, (2003a). 
Nevertheless, the clinical event that arises from coronary atherosclerotic plaque 
formation is myocardial ischemia (decreased coronary perfusion).  According to Preuss 
et al. (1987), there are three major types of ischemia: (1) tolerable ischemia has a low 
degree of reduced blood flow; (2) critical ischemia reflects a modestly severe flow 
reduction; and (3) lethal ischemia has a severe flow reduction and is the limit of 
myocardial survival.  Lethal ischemia, if left untreated, can lead to irreversible cell 
necrosis [myocardial infarction (MI)]. 
1.1.1.3 Theories of Atherosclerosis 
 Although there are several theories of atherogenesis they all have a central 
concept centered on the following factors: (1) lipid involvement in the formation of a 
lesion (2) monocyte migration and proliferation, and (3) smooth muscle proliferation. 
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 Response to Injury Hypothesis 
 The most commonly accepted theory of atherosclerosis is the Response to Injury 
Hypothesis.  It was first proposed by Virchow in 1956, was later modified and expanded 
by Ross and Glomset (1976), and was updated subsequently by Ross in 1986.  Their 
theory of atherosclerosis is based upon endothelial damage caused by chemical, 
mechanical, immunological or toxicological insult.  Endothelial damage leads to 
endothelial dysfunction, which initiates a lesion and causes exposure of the 
subendothelial tissue. The previous events may be responsible for the insudation of 
plasma lipoproteins into the arterial wall.  Furthermore, the progression of the lesion 
involves monocyte and platelet chemotaxis and adherence to the endothelium (Faruqui 
et al. 1994). The formation of endothelial gaps (20-60 nm) may be due to structural 
changes in the microvasculature where there is endothelial cell contraction or 
intercellular endothelial cell retraction and cytoskeletal reorganization under the 
influence of interleukins, tumour necrosis factor (TNF) and interferon. Successively, 
monocytes, and T lymphocytes diapedes through the endothelium into the extravascular 
space where monocytes are subsequently converted into mature macrophages. Tissue 
macrophages phagocytize lipids, and become immobile foam cells, which are the early 
atherosclerotic fatty streak lesions (Ross, 1993). 
 The adhesion of white blood cells to the endothelial surface is accomplished 
through endothelial-dependent counter receptor mechanisms.  The increase in 
recruitment and adhesion of monocytes and T lymphocytes is due to endothelial-
dependent counter receptor mechanisms, which form specific sets of adhesion 
molecules.  Monocyte expression of very late antigen-4 (VLA-4) unites with its vascular 
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endothelial counter receptor, vascular cell adhesion molecule (VCAM-1) to provide 
selective adhesion (Gimbrone, 1995).  There are various other endothelium-dependent 
counter receptor systems contributing to the increase in adherence of monocytes to the 
endothelium, such as the selectin and integrin varieties: (1) intercellular adhesion 
molecule 1 which interacts with CD11/CD18-integrin complex, (2) endothelial derived 
monocyte chemotactic protein-1 (MCP-1), (3) interleukin 1 (IL-1), (4) TNF, and (5) 
hypercholesterolemic serum lipoproteins (Gimbrone, 1995; Denholm and Lewis, 1987).   
Prasad (2003a) described several growth modulators produced by macrophages, 
smooth muscle cells, endothelial cells, and T lymphocytes which have paracrine and or 
autocrine effects. Paracrine effects are expressed when growth modulators act upon 
other cell types in the vicinity. However, an autocrine effect is manifest when growth 
modulators act upon the cells that have produced them (Denholm and Lewis, 1987).  
Macrophages produce the following paracrine acting growth modulators: (1) platelet-
derived growth factor (PDGF); (2) heparin-binding epidermal growth factor (HB-EGF); 
(3) cytokines (IL-1, TNF); (4) oxidized low density lipoproteins (OX-LDL); and (5) 
basic fibroblast growth factor and transforming growth factors α and β (bFGF, TGF-α, 
TGF-β) which all modulate the action of adjacent cells (Gimbrone, 1995).  Furthermore, 
TGF-β which is also produced by T lymphocytes has two main functions: (1) inhibition 
of smooth muscle cell replication; and (2) initiation of the production of connective 
tissue and matrix such as elastic fiber proteins, collagens and proteoglycans. In addition, 
smooth muscle cells form oxidized LDL (OXLDL), macrophage colony stimulating 
factor (M-CSF) and granulocyte-monocyte colony stimulating factor (GM-CSF) all of 
which induce monocyte differentiation into mature macrophages (Denholm and Lewis, 
1987).  Colony stimulating factor plays an important part in macrophage immobility and 
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replication.  According to Prasad (2003a), smooth muscle and endothelial cells also 
control growth by the production of PDGF, bFGF, TGF, insulin like growth factor I 
(IGF-I), and cytokines (IL-1, TNF-α).  Likewise, cytokines exert an autocrine effect on 
smooth muscle by stimulating smooth muscle proliferation, and a paracrine effect by 
eliciting endothelial activation (Prasad, 2003a).  
In summary, the response to injury hypothesis is based upon insult by 
hyperlipidemia or other risk factors that induce endothelial injury and dysfunction 
causing platelet and monocyte adhesion, and liberation of cytokines, chemo-attractants, 
and growth regulators.  Consequently, this sequence of events triggers smooth muscle 
cell proliferation, chemotaxis and emigration of more monocytes with eventual 
macrophage lipid retention creating a vicious cycle that leads to the genesis of the 
atherosclerotic fatty streak lesion. 
Oxidative Hypothesis 
In the oxidative hypothesis the production of the atherosclerotic fatty streak 
lesion is due to low-density lipoprotein cholesterol (LDL-C) oxidation, which then 
accumulates in immobile tissue macrophages termed foam cells (Henriksen et al. 1981).  
Plasma lipoprotein and LDL-C set the stage for atherogenesis by being oxidized by 
smooth muscle cells, macrophages and endothelium (Keany and Vita, 1995).  The 
oxidation of LDL-C to minimally modified LDL-C (MMLDL) stimulates endothelial 
and smooth muscle cells to produce monocyte chemotactic protein 1 (MCP-1) which in 
turn increases monocyte migration to the subendothelial area (Chisolm, 1991). 
Furthermore, MMLDL is likewise oxidized to OXLDL which can directly cause 
endothelial damage, trigger additional monocyte migration, and stimulate the release of 
MCP-1 and M-CSF from endothelial cells.  Conjointly, OXLDLs also serve as ligands 
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for the scavenger receptor of macrophages (Steinberg, 1991) as outlined by Prasad 
(2003a).  Thus, macrophage engulfment of OXLDL renders them to become OFR 
releasing, immobile foam cells, stationary at the focus of the lesion as described by 
Prasad (2003a).  Finally, the endothelial adhesion of monocytes depends upon cytokines 
and chemoattractants such as IL-1β and M-CSF which effect surface expression of 
endothelial–leukocyte adhesion molecules (ELAMS) (Schwartz et al 1993).  
1.1.2 Risk Factors for Atherosclerosis 
 As reviewed by Prasad (2003a) the risk factors for atherosclerosis are divided 
into two general categories (1) major risk factors (which are further subdivided into 
nonmodifiable and potentially controllable categories), and (2) minor risk factors. 
1.1.2.1 Major Risk Factors 
Nonmodifiable Risk Factors 
As described by Prasad (2003a), nonmodifiable risk factors are those inherent 
factors, which cannot be changed.  They include genetic abnormalities, increasing age, 
positive family history of atherosclerosis, and male gender. 
Potentially Controllable Risk Factors 
1.1.2.1.1 Hypertension.  
 Hypertension is an independent risk factor for CAD and other atherosclerotic 
disease (Kannel, 1975).  In addition, greater risks of atherosclerotic disease 
complications arise when the diastolic pressure is greater than 115mm Hg.  However, 
other studies have demonstrated that a better indicator for hypertension-induced CAD is 
an elevated systolic pressure (Rosenman et al. 1976). Interestingly, atherosclerosis in 
hypertension may occur because of induced vascular wall growth, particularly medial 
smooth muscle cell hypertrophy and intimal hyperplasia.  In addition, excitation from 
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the sympathetic nervous system and vasoactive substances can elicit smooth muscle 
hyperplasia and replication (Owens, 1989).  Common vasoactive substances such as 
serotonin, endothelin, and thrombin can cause smooth muscle replication, whereas 
angiotensin II can cause smooth muscle hyperplasia in patients with hypertension 
(Chobanian, 1990).  Similarly, hypertension may be induced by variability between 
oxidants and antioxidants. Prasad (2003a) has summarized oxidative stress and 
consequent hypertension-induced atherosclerosis.  The vasoconstriction elicited by the 
superoxide anion could have a major function in essential hypertension (Nakazano et al 
1991).  Conversely, the administration of the antioxidant superoxide dismutase (SOD) 
has been reported to decrease hypertension in rats and hypertensive patients (Sagar et al. 
1992). In addition, three antioxidants (vitamin C, glutathione, and thiopronine) have 
elicited an acute antihypertensive effect in patients with hypertension (Ceriello et al. 
1991).  Panza et al. (1990) have also reported that if hypertensive patients have elevated 
levels of superoxide anions then the effect of nitric oxide (NO) is inhibited.  Therefore, 
the vasodilatory effect of NO is suppressed, and hypertension becomes marked.  It is 
also speculated that elevated serum OFR levels observed in hypertensive patients could 
result in endothelial dysfunction, and induce atherogenesis (Prasad, 1997b). 
1.1.2.1.2 Hypercholesterolemia  
Hypercholesterolemia is a strong independent risk factor for CAD and 
atherosclerosis.  Consequently, mortality is high in populations with elevated levels of 
cholesterol. Elevated plasma cholesterol levels have been associated with increased 
probability of the development of MI (Castelli, 1988).  According to the follow-up of the 
Framingham Heart Study (Anderson KM et al. 1987), the range for total cholesterol 
which correlates with borderline elevated risk for the development of CAD is from 5.15 
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to 6.18 mmol/L, and the range for high risk total cholesterol is ≥ than 6.20 mmol/L.  In 
addition, the risk for the development of CAD increases by 2 to 3% for each 1% increase 
in total cholesterol (Castelli, 1986). 
1.1.2.1.3 Triglycerides 
 Many prospective studies have indicated that elevated triglyceride levels are 
associated with increased risk for the development of CAD (Steinberg and Wiztum, 
1990).  Atherogenesis is induced by the metabolism of high levels of triglycerides. 
Specifically, elevated levels of very low-density lipoprotein triglycerides (VLDL TG) 
result in the formation of an array of low-density lipoproteins (LDL-C) and low 
concentrations of high-density lipoproteins (HDL-C) both of which are atherogenic in 
nature (Austin, 1989).  Similarly, high triglyceride levels may induce a procoagulant 
state, which could lead to thrombosis and MI. The mechanism by which elevated levels 
of triglycerides produce a procoagulant state is due primarily to their ability to induce: 
(1) increases in factors VII and X; (2) activation of phospholipid complexes; (3) 
production of fibrin and thrombin; and (4) inhibition of transplasminogen activator (tPA) 
(Castelli, 1986; Castelli, 1988; Austin, 1989).  
1.1.2.1.4 LDL-Cholesterol (LDL-C) 
It is postulated that LDL are correlated with increased atherogenesis because of 
their small size and increased susceptibility to be oxidized.  An LDL of less than 3.6 
mmol/L is considered to be normal; 3.36 to 4.11 mmol/L is borderline; and greater than 
4.14 mmol/L represent high-risk values for the development of CAD (Austin et al. 
1990).    
Under physiological circumstances LDL are responsible for the transport of 
endogenous triglycerides to the periphery for storage.  The endothelial LDL receptor 
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allows sequestration by endocytosis of LDL into the cytoplasm with the subsequent 
release of cholesterol for tissue use (Austin et al. 1990).  
1.1.2.1.5 HDL-Cholesterol (HDL-C) 
 Numerous reports have demonstrated an inverse relationship between HDL 
levels with risk of development of CAD.  Hence, the prevention of atherosclerosis is 
closely related to the reverse cholesterol transport from the tissues to the liver where it is 
cleared by a hepatic HDL receptor (Anderson et al. 1978).  The two subgroups of HDL 
are HDL-2, which is composed of small particles, and HDL-3, which consists of larger 
particles.  In addition, elevated HDL levels exert a cardio protective effect and delay the 
rate of atherogenesis (Montali et al. 1994) perhaps by retarding the permeability, 
transport, and retention of LDL in the arterial wall (Khoo et al. 1990).  Additionally, 
elevated HDL concentrations may exert a cardioprotective effect by inhibiting the 
oxidation of LDL (Parthsarathy et al. 1990).  As outlined by Prasad (2003a), elevated 
HDL levels are observed in people who exercise; consume moderate amounts of alcohol, 
and patients with hyperthyroidism.  Yet reduced HDL levels are seen in patient 
administered thiazides or β blockers, cigarette smokers, obese patients, and those who do 
not exercise.  Thus, patients with low levels of HDL may have an increased risk of 
atherogenesis. “For every 1mg/dL decrease in HDL cholesterol concentration, the risk 
for CAD is increased by 2-3%” (Grundy, 1995).  
1.1.2.1.6 Lipoprotein (a) 
Lipoprotein (a) [LP (a)] is a form of LDL-C which consists of two large 
glycoproteins, apolipoprotein (a) and apolipoprotein (b) that are covalently bonded by a 
disulfide bridge (Grundy, 1995).  LP (a) is structurally similar to the plasma protein 
plasminogen which, when activated, functions to dissolve fibrin stands and decrease clot 
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formation.  Essentially, LP (a) competes with plasminogen for binding sites and impairs 
fibrinolysis (Loscalzo et al. 1990).  The mechanisms of LP (a) participation in the 
genesis of atherosclerosis are varied.  For example, macrophages in atherosclerotic 
plaques express a VLDL receptor that can bind to, and mediate the catabolism of LP (a) 
leading to increases in cholesterol retention, LDL oxidation, and foam cell formation 
(Palabrica et al. 1995; Hansen et al. 1994).  Macrophage foam cell formation could be 
due to LP (a) induction of intracellular adhesion molecule -1, which may act to 
immobilize macrophages (Takami et al. 1998), thus contributing to the fatty streak 
atherosclerotic lesion.   Additionally, LP (a) may cause damage to endothelial 
constituents that respond to vasodilatory stimuli (Schachinger et al. 1997).  
Consequently, a decreased response to vasodilatory stimuli may induce hypertensive 
related atherosclerosis. 
There have been conflicting reports concerning the relationship between LP (a) 
and the development of CAD.  Several studies have suggested that LP (a) is an 
independent predictor of risk for CAD (Bostrom et al. 1994, and 1996; Schaefer et al. 
1994; Austin MA et al. 1990; Ariyo et al. 2003).  Other reports have indicated that there 
is no correlation between LP (a) and CAD.  Despite this conflict, there appears to be 
agreement that LP (a) has a capacity in predicting the risk of development of CAD in 
patients with concurrently elevated cholesterol levels.  According to Von Eckardstein et 
al. (2001), male patients with LP (a) concentrations ≥ 20 mg/dL were 2.7 times more 
likely to experience a coronary episode (nonfatal or fatal myocardial infarction and/ or 
sudden death) than those with lower levels.   
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1.1.2.1.7 Apolipoproteins 
Lipoproteins are composed of protein, phospholipids, triglycerides, and esterified 
and unesterified cholesterol. The apolipoproteins are the protein constituents of the 
lipoprotein, and they function as cofactors for enzymes and ligands for receptors. There 
are several different apolipoproteins, and derangements in their metabolism lead to 
abnormalities in lipid metabolism and atherogenesis (Rader et al. 1994). 
 1.1.2.1.8 Diabetes Mellitus (DM) 
 Diabetes mellitus is an absolute risk factor for the development of atherogenesis. 
Specifically, in diabetic patients, the occurrence of myocardial infarction is twofold that 
of non-diabetics (Lyons, 1993).  As outlined by Prasad (2003a), the exact mechanism of 
atherogenesis in diabetics is unclear; however there is growing evidence that there could 
be several ways that diabetes could induce atherosclerosis. For instance, diabetes can 
stimulate LDL-hypercholesterolemia.  Prasad et al. (1994) described the probability that 
hypercholesterolemia could increase the concentration of oxygen free radicals and 
induce endothelial cell injury thereby stimulating the development and maintenance of 
atherogenesis.  In type II diabetics, insulin levels are independent of the hyperglycemic 
state.  Thus, normal insulin and IGF-I levels can increase the proliferation of growth 
factor, and induce the insudation of LDL by smooth muscle cells (Sonio et al. 2004).  
Diabetics also exhibit glycation, which is the nonenzymatic binding of glucose to 
proteins resulting in augmented uptake of LDL by macrophages (Lyons, 1993).  
Similarly, glycoxidation products, the free radical stimulated oxidation of lipoproteins 
are thought to be atherogenic.  Likewise, glycosylation end products are postulated to be 
atherogenic due to their chemotaxis of monocytes.  Finally, the ORs produced by 
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hyperglycemia in diabetics may induce dysfunctional endothelium which is involved in 
the genesis of atherosclerosis (Prasad and Kalra, 1993; Baynes, 1991). 
1.1.2.1.9 Cigarette Smoking 
 Smoking is a major independent risk factor for the development of 
atherosclerosis, and patients who smoke one or more packs of cigarettes per day have an 
elevated risk of 2.5 to 3.2 times higher than non-smoking patients (Bazzano et al. 2003).   
Men in particular who smoke one pack of cigarettes per day have 3 to 5 times the risk of 
the development of ischemic heart disease (IHD) than non smokers (Fielding, 1985).  
Similarly, women over the age of thirty-five who smoke cigarettes and take oral 
contraceptives have an elevated risk of the development of IHD (Friedman et al. 1979).  
However, the risk in the development of CAD decreases abruptly with the 
discontinuance of smoking (Friedman et al. 1979).  The mechanisms of atherogenesis 
from cigarette smoking are complicated.  The by products of smoking such as peroxyl 
radicals may induce endothelial injury which in turn stimulates and maintains 
endothelial dysfunction and atherogenesis.  Moreover, the levels of ORs are increased 
by smoking through augmented PMNL stimulation from complement activation (Kalra 
et al. 1991).  
1.1.2.2 Minor Risk Factors 
1.1.2.2.1 Alcohol 
 Overindulgence of substantial amounts of alcohol is absolutely correlated with 
the development of CAD (Schmidt and deLint, 1972).  On the other hand, reasonable 
consumption of alcohol has been correlated with a decreased risk of the development of 
CAD (Hennekens et al. 1978) due to the protective effect of elevation in HDL levels and 
lowering of LDL concentrations in the serum.  Prasad (2003a) has summarized the 
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oxidative stress with alcohol consumption. Alcohol increases triglyceride and OR levels 
which have been shown to be atherogenic.  The potential propagation of ORs from 
alcohol abuse are metabolism of acetaldehyde (via the metabolism of ethanol), 
microsomal ethanol oxidizing, and the acetaldehyde-induced stimulation of the plasma 
membrane of hepatocytes to stimulate PMNLs to produce superoxide anions 
(Cederbaum et al. 1977; Klein et al. 1983; Muller, 1987; Puig and Fox, 1984; Williams 
and Barry, 1986; Winston and Cederbaum, 1982). 
1.1.2.2.2 Coffee 
 Prasad (2003a) summarizes the effect of coffee on the development of 
atherosclerosis. Atherosclerosis has not been correlated to coffee consumption in past 
prospective studies (Kannel and Dawber, 1973).  Yet, present studies have shown a 
correlation between coffee consumption and elevated risk of CAD.  Furthermore, 
myocardial infarction has been related to coffee consumption in a retrospective case 
control study (Jick et al. 1973).  In animal models where coffee consumption was 
studied, the results demonstrated increased myocardial irritability and a decreased 
ventricular fibrillation threshold, which suggests a probable cause of sudden death in 
human coffee consumption (Bellet et al. 1972).  Similarly, coffee related atherogenesis 
has been correlated to increased serum TG and cholesterol levels (Thelle et al. 1987).  
Essentially, an elevated LDL is a consequence of the consumption of ground coffee 
beans boiled directly with water.  The hypercholesterolemia resulting from boiled coffee 
is due to diterpine alcohols.  The diterpine alcohol cafestol has been demonstrated to 
lower bile acid synthesis and down regulate the LDL receptor, which can cause an 
increase in serum cholesterol in boiled coffee drinkers.  Conversely, the 
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hypercholesterolemic effect is not seen when coffee is purified through a filter because 
the diterpines are removed (Thelle et al. 1987).   
1.1.2.2.3 Infection 
 Prasad (2003a) has summarized oxidative stress and atherosclerosis with 
infection.  Recent reports have suggested that specific types of infections may have a 
part in atherogenesis by creating a low-grade constant state of acute or chronic 
inflammation that can result in endothelial dysfunction, which is the initial step in 
proatherogenic properties (Gabay and Kushner, 1999). Interestingly, animal models 
have demonstrated that continuous susceptibility to circulating endotoxins produces a 
risk factor for atherosclerosis (Lehr et al. 2001).    Infections can also stimulate the 
production of heat shock proteins (HSP), which are stress proteins that respond to 
injurious stimuli.  Those induced subsequent to injurious excitation; presumably act in 
refolding denatured polypeptides to re-establish their function before cell dysfunction or 
death (Xu et al. 2000; Zhu et al. 1999; Burian et al. 2001; and Pockley, 2002).   
Specifically, HSP 60 causes human macrophages to produce TNF-α and matrix 
metalloproteinase’s.  Earlier in the section on “Theories of Atherosclerosis”, the 
cytokine TNF-α and its role in growth modulation in the development of early fatty 
streak lesion was discussed.  Moreover, HSP 60 may also trigger endothelial cell 
expression of monocyte adhesion molecules E- selectin, ICAM-1, VCAM-1, and IL-6.  
Finally, HSP 60 has been positively associated with other markers of inflammation and 
with the existence of CAD (Xu et al. 2000; Zhu et al. 1999; Burian et al. 2001; and 
Pockley, 2002).    
The principal organisms studied which exhibited a relationship between acute or chronic 
inflammatory infection and risks of developing atherosclerosis are Chlamydophila 
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pneumonia (C. pneumonia), human cytomegalovirus (CMV), and Helicobacter pylori. 
However, numerous other viruses have been associated with the proatherosclerotic 
events (Smeeth, 2004). 
 Chlamydophila Pneumonia 
  C. pneumonia, a known and classified human pathogen from respiratory tract 
infection is transferred from the lungs to the vascular wall by circulating monocytes.  It 
can be sustained within the monocyte without lysis for up to ten days (Grayston et al. 
1986 and Gieffers et al. 2001).  In animal models and in human subjects, C. pneumonia 
induced atherosclerosis may be produced by alternative methods.  First, C. pneumonia 
may stimulate the expression of the procoagulant plasminogen activator inhibitor-1 
(PAI-1) protein and the proinflammatory cytokine interleukin-6 which could potentially 
increase atherogenesis by influencing thrombus formation (Dechend, 1999).  Secondly, 
the observation of aortic tissues from normocholesterolemic and hypercholesterolemic 
groups of mice with manipulated LDL receptor deficiency in the presence of C. 
pneumonia resulted in amplified atherosclerosis in only the hypercholesterolemic group.  
Thus, it is possible that an atherosclerotic lesion induced by hypercholesterolemia is 
present prior to infection by C. pneumonia (Hu et al. 1999).  Chronic infection can be 
detected by serology or polymerase chain reactions (PCR) when there is an appearance 
of elevated titers of immunoglobulin G (IgG), or immunoglobulin A (IgA) antibodies to 
C. pneumonia in the blood (Wong et al. 1999).   In human subjects serologic and PCR 
evaluations show that positive and negative correlations exist between circulating C. 
pneumonia antibody titers and CAD.  Specifically, meta-analysis prospective studies of 
IgG and IgA titers revealed no significant associations and weak correlations between 
CAD, and these titers respectively (Danesh et al. 2000; Danesh et al. 2002).  On the 
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other hand, elevated titers of C. pneumonia antibody have been strongly correlated with 
a high probability of the development of adverse cardiac events in case control studies 
that have differentiated serologic results for C. pneumonia in patients with CAD with 
matched controls (Siscovick et al. 2000; Ridker et al. 1999).  Overall, there is a positive 
correlation between C. pneumonia and atherosclerosis. It is still debatable however, as to 
whether the virus is a stimulus for inflammation and chronic infection or a component of 
atherosclerotic tissue.  Most viruses respond to antibiotic therapy thus, many antibiotic 
trials have been undertaken.  Even though C. pneumonia may not be able to be removed 
from circulating monocytes with antibiotics, they may provide an anti-inflammatory 
effect (Gieffers et al. 2001).  Nevertheless, meta-analysis of random control studies 
using the antibiotics azithromycin and roxithromycin to treat patients with stable CAD, 
acute MI, an acute coronary syndrome (ACS), coronary restenosis, and peripheral artery 
disease against patients receiving a placebo has revealed that there was no significant 
difference between groups in attenuating cardiovascular episodes or death from three 
months to five years (Wells et al. 2004; Anderson et al. 1999). Thus, there was no 
benefit in prescribing antibiotic therapy to patients with atherosclerosis. 
Human Cytomegalovirus 
 Infection with cytomegalovirus has been correlated with the development of 
atherosclerosis in an abundance of studies.  However, there are some studies that show 
no relationship between the two (Adler et al. 1998; Blum et al. 1998; Sorlie et al. 2000).  
The mechanism of action in which CMV induces the development of atherosclerosis 
may be through various pathways.  According to Muhlestein et al. (2000), the 
combination of increased serum levels of inflammatory indicators such as C- reactive 
protein (CRP), and interleukin-6 (IL)-6 with CMV seropositivity is an absolute predictor 
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of mortality.  Consequently, it is suggested that certain patients who develop 
atherosclerosis have had an inflammatory response from CMV, and those patient’s in 
whom the inflammatory response was absent were resistant (Zhu et al. 1999).     Another 
concept of how CMV infection may motivate the formation of atherosclerosis is by 
promoting the expression of the Type A scavenger receptor for OXLDL on vascular 
smooth muscle cells (Zhou et al. 1996).  Thus, an increased expression of this receptor 
contributes to the formation of foam cells and the genesis of the early atherosclerotic 
fatty streak lesion.  Finally, it is also postulated that CMV infection may accelerate 
neointimal reaction to vascular injury whether the virus exists in the vascular wall or not 
(Zhou et al. 1999).  Consequently, endothelial injury is known to lead to endothelial 
dysfunction, which greatly increases the likelihood of the development of 
atherosclerosis.  
Other Pathogens 
 Dental infections of the teeth and gingivae such as peridontitis and caries have 
been associated with the development of CAD.  Lactobacillus, Haemophilus influenzae, 
Streptococci pneumonia, viridans and nonhemolytic streptococci are a few of the 
oropharyngeal flora implicated in the development of atherosclerosis (Mattila et al. 
1993; Prasad, 2003a).  In addition, Helicobacter pylori infection has been associated 
with atherosclerosis and MI.  However, this correlation is unclear at this time (Patel et 
al. 1995; Gunn et al. 2000).  Finally, Prasad (2003a) reported that the total amount of 
pathogens to which a patient is exposed is termed the pathogen burden, and it is perhaps 
related to the existence and complexity of CAD, and is possibly a better indicator of 
endothelial dysfunction than any one particular pathogen. 
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 1.1.2.2.4 C-reactive protein (CRP) 
 Prasad (2003c) gave an account of C-reactive protein as being an acute phase 
reactant protein that serves as a novel biomarker for inflammation and atherosclerosis.  
Generally, it is a risk factor for cardiovascular disease and may specifically predict the 
development of MI and stroke in healthy individuals (Pearson et al. 2003).   According 
to Gauldie et al. (1987), the stimulation of monocytes and macrophages during 
inflammation induces them to release cytokines such as IL-6, IL-1 β, TNF-α, interferon 
λ and transforming growth factor β.  Cytokines in turn stimulate hepatocytes to release 
the major positive acute phase proteins CRP and serum amyloid A.  The major negative 
acute phase proteins are albumin, transferrin and transthyretin (Kushner and Feldmann, 
1978).  Those proteins whose plasma levels increase by at least twenty–five percent 
during inflammatory circumstances are termed positive acute phase proteins.  
Conversely, those proteins whose plasma concentrations decrease by at least twenty-five 
percent are termed negative acute phase proteins (Morley and Kushner, 1982).  As 
specified by Pearson et al. (2003) CRP elicits numerous reactions such as complement 
activation, accelerated neutrophil phagocytosis and release of ORs, stimulation of 
adhesion molecules, production of tissue factor, and increases in platelet aggregation.   
A postulated primary proinflammatory function of CRP is related to its affinity for 
phosphocholine (PC), a host microbe ligand that is expressed on the phospholipid 
components of damaged cells and pathogens.  Thus, through an innate immune response 
the binding of CRP to PC allows the detection of foreign pathogens by activation of the 
classical complement pathway, thereby inducing the elimination of these target cells 
(Volanakis, 1997; Hoffmann et al. 1999).  CRP has anti-inflammatory roles as well. For 
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instance, one study demonstrated that increased CRP levels caused a detachment of L-
selectin thereby decreasing endothelial neutrophil adhesion (Zouki et al. 1997).  
Equivocally, Prasad (2003c) detailed that CRP may enhance the expression of adhesion 
molecules by increasing oxidative stress and decreasing antioxidant production.  
Nevertheless, Gershov et al. (2000) have shown that CRP stimulated macrophage 
engulfment of apoptotic cells, and the attachment of CRP to lymphocytes subjected to 
apoptosis inhibited complement activation and lysis. 
As previously alluded to by Prasad (2003c) CRP may cause atherogenesis by the 
production of oxygen free radicals and expression of adhesion molecules.  The oxidative 
theory of atherosclerosis is based upon the pathophysiological generation of ORs.  CRP 
directly stimulates monocytes and neutrophils to produce ORs, and indirectly induces 
OR production by complement activation, stimulation of platelet activating factor and 
expression of cytokines.  Moreover, CRP is also thought to induce the production of 
MCP-1 by arterial endothelial cells (Ridker et al. 1998). 
There appears to be a body of evidence that levels of CRP are correlated with serum 
lipids.  Elevated levels of CRP have been shown in LDL- hypercholesterolemia resulting 
from cholesterol-enhanced diets.  Conversely, low CRP levels are observed in dietary 
cholesterol deficient diets (Verhamme et al. 2002). In addition, elevated plasma Lp (a) is 
correlated with increased concentrations of CRP.  Several studies have demonstrated 
that hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) may be used to 
reduce plasma CRP levels in patients with hyperlipidemia (Moon and Kashyap, 2002; 
Verhamme et al. 2002; Ridker et al. 1998).  Moreover, the incorporation of niacin and 
lovastatin administered to patients with hyperlipidemia lowers serum LDL and TG, and 
decreases LP (a) and CRP by 25 and 24% respectively (Moon and Kashyap, 2002). 
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 1.1.2.2.5 Homocysteine (tHcy) 
 Hyperhomocysteinemia (>15 µmoles/L) has been identified as an independent 
risk factor for the development of atherosclerosis and deep vein thrombosis (Lee and 
Prasad, 2002; Gaustadnes et al. 2000). Prospective and cross sectional investigations 
have positively correlated tHcy with elevated risk for the development of coronary heart 
disease (Stampfer et al. 1992).  Homocysteine is a sulphur containing intermediary 
amino acid which is derived by the demethylation of methionine (Shipchandler et al. 
1995).  The primary source of methionine is animal protein (Hankey and Eikelboom, 
1999). Trans-sulphuration is the biochemical reaction in which homocysteine is 
catabolized to sulphate under the influence of vitamin B6 and excreted in the urine.  
However, during transmethylation folate and vitamin B12 catalyze the remethylation of 
homocysteine to methionine.  Total homocysteine (tHcy) exists in plasma in the 
following four forms (1) circulating as a free thiol {1%}; (2) bound to proteins {80-
90%} (i.e. albumin) by disulphides; (3) as a dimer {5-10%}(bound with itself); and (4) 
bound with different thiols {5-10 %} (i.e. cysteine) (Hankey and Eikelboom, 1999).  
Increases in the plasma concentration of tHcy may be due to genetic insufficiencies of 
the enzymes needed for its metabolism, to nutritional deficits in vitamin cofactors, or to 
other circumstances such as drugs and medical conditions (diabetes) (Kang, 1995; Kang 
and Wong, 1996; Mezzano et al. 1999; Sonio et al. 2004).  Similarly, low intake and 
plasma concentrations of folate and vitamins B6 and B12 have been associated with 
increased plasma tHcy levels (Lee and Prasad, 2002). 
One major property of tHcy is its ability to induce atherogenesis (Clark et al. 
1991).  The pathological hallmarks of homocysteine induced endothelial injury are the 
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formation of platelet saturated thrombi, smooth muscle hypertrophy, elastic lamina 
separation, intimal expansion and the formation of S-nitroso-homocysteine (MuCully, 
1969; Harker et al. 1976; Prasad, 1999).  Homocysteine also causes atherogenesis by 
increasing DNA synthesis of a gene called Cyclin A which in turn stimulates an 
uncontrollable replication of cells in one region within the lining of blood vessels. In 
addition, tHcy may stimulate atherosclerosis by deranging the endothelium vasomotor 
regulation of nitric oxide by the formation of S-nitroso-homocysteine through a process 
of nitrosation (NO reacting with homocysteine in the presence of water).  S-nitroso-
homocysteine causes vascular injury by decreasing the protective effect of NO reserves, 
thus inhibiting physiological smooth muscle vasodilation and membrane stability 
(Hankey and Eikelboom, 1999; Langman, 2000; Fonseca et al. 1999; D’Angelo and 
Selhub, 1997; Ling and Hajjar, 2000; Tsai et al. 1994 and 1996; Prasad, 1999).  Finally, 
according to Prasad (1999), homocysteine has been postulated to promote 
atherosclerosis by the stimulation of oxidative injury to the endothelium, which is a 
crucial step in the response to injury hypothesis.     
1.1.3 Oxygen Radicals and Atherosclerosis 
 Prasad (2003b) outlined ORs and their relationship to atherosclerosis.  Within an 
atom there is a nucleus, which is surrounded by orbitals that contain spinning electron 
pairs.  Prasad (2003b) defined a free radical as an extremely toxic intermediate reactive 
atom or molecule with a short half-life that has one or more unpaired electrons in its 
outer orbital.  However, an oxygen free radical (OFR) is a compound that is produced 
from molecular oxygen and has gained less than four electrons.  Reactive oxygen 
species (ROS) also termed oxygen radicals (ORs) such as hydrogen peroxide and 
hyperchlorous acids are derived from molecular oxygen, and they contain an even 
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quantity of electrons in their outer shell (Lindqvist and Nordstrom, 2001).  Many ROS 
exist, and they have been shown to contribute to the development of various human 
diseases such as hypercholesterolemic atherosclerosis, ischemia-reperfusion injury, 
peripheral vascular disease, heart failure, diabetes mellitus, Parkinson’s disease, 
Alzheimer disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), hemorrhagic 
and endotoxic shock, burns, cataracts, rheumatoid arthritis, asthma and cancer (Prasad, 
1999; Prasad et al. 1994; Pattanaik and Prasad, 1998; Kapoor and Prasad, 1996; Babior, 
1984; Baynes, 1991; Lindquist and Nordstrom, 2001).   The oxidative hypothesis of 
atherosclerosis is based upon endothelial injury from oxidation of LDL (Henriksen et al. 
1981).  The oxidation of LDL could be due to the production of ORs (Keany and Vita, 
1995).  Interestingly, endothelial injury activates complement (C3 and C5) (Webster et al. 
1980). Activated complement, platelet-activating factor (PAF), leukotrienes B4 (LTB4) 
and TNF stimulate PMNLs to release oxygen free radicals (Ford-Hutchinson et al. 1980; 
Braquet et al. 1989; Zoratti et al. 1991; Paubert-Braquet et al. 1988).  This evidence 
suggests that there could be increased OR production contributing to the genesis of 
atherosclerosis. 
1.1.3.1 Formation of Oxygen Radicals 
 Prasad (2003b), particularized, the five common oxygen free radicals are the 
superoxide anion (O2-), the hydroxyl radical (OH.), the peroxyl radical (ROO.), the 
alkoxyl radical (RO.), and the hydroperoxyl radical (HOO.).  Oxygen species that have 
an even number of electrons in their outer orbital, for instance hydrogen peroxide 
(H2O2), and hypochlorous acid (HOCl) are termed reactive oxygen species (ROS) not 
oxygen free radicals.  The magnitude of ORs generated is dependent upon the severity of 
tissue injury (i.e. ischemia), the activation and recruitment of generators of ORs (i.e. 
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PMNLs), the level of oxygen in solution, and the presence of endogenous or exogenous 
scavengers or inhibitors (Prasad, 1998; Kapoor and Prasad, 1996; Babior, 1984; Baynes, 
1991). 
 1.1.3.2 Superoxide Radical (O2 -) 
 During physiological respiration within the internal mitochondrial membrane, 
superoxide radicals may be formed from the reduction of molecular oxygen by the 
addition of four electrons to produce water.  This reactive oxygen metabolite is further 
reduced to form hydrogen peroxide (H2O2) and hydroxyl radicals (OH.).  Specialized 
phagocytic cells such as macrophages produce (O2-) by means of an oxidative burst to 
destroy engulfed pathogens (Fantone and Ward, 1982; McCord and Fridovich, 1973; 
McCord, 1985). Moreover, the ubiquitous flavin cytosolic enzyme xanthine oxidase 
catalyzes the formation of superoxide anions from hypoxanthine and oxygen (Babior et 
al. 1973).  According to Warren and Ward (1986), the superoxide radical oxidizes 
catecholamines, vitamin C, homocysteine, and sulphates.  It also functions in the 
inhibition of many enzyme systems.  The superoxide radical may produce toxicity but it 
has restricted reactivity with lipids.  Thus, the majority of the injurious effects may be 
due to the secondary production of extremely toxic .OH through Haber-Weiss reactions 
(Fantone and Ward, 1982; McCord and Fridovich, 1973; McCord and Roy, 1982; 
McCord, 1985).  
1.1.3.3 Hydroxyl Radical (.OH) 
 As reviewed by Prasad (2003b) the .OH is an extremely reactive oxygen 
metabolite produced by the metallic (copper or iron) induced disunion of O2- and H2O2 
by the Fenton or Haber-Weiss reactions.   In addition, superoxide anion reacts with nitric 
oxide (NO) to form peroxynitrite (ONOO-) in endothelial cultures in human neutrophils 
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(Kooy and Royall, 1994; Carreras et al. 1994). During normal cellular metabolism 
peroxynitrite forms the very volatile peroxynitrous acid, a potent oxidant that quickly 
decomposes to hydroxyl radical and nitrogen dioxide (Beckman et al. 1990; Koppenol et 
al. 1992).  Interestingly, hydroxyl radicals have been demonstrated to induce relaxation 
of isolated aortic strips in animals (Bharadwaj and Prasad, 1994).  Prasad and Bharadwaj 
(1996) also introduced scavengers of superoxide anion and hydroxyl radical to isolated 
rabbit aortic preparations and showed that acetylcholine (Ach) increases levels of NO. 
which reacts with superoxide anion to form hydroxyl radical that  induces vascular 
relaxation. These results demonstrated that Ach-induced relaxation is mediated by 
hydroxyl radical.  Thus, the .OH produced in physiological concentrations may not 
damage endothelial cell function, however the generation of high concentrations of .OH 
under pathological conditions may promote the harmful effects of perioxidation of lipid 
membranes that may cause damage in biological systems and induce atherogenesis 
(Prasad and Bharadwaj, 1996).   
1.1.3.4 Nitric Oxide (NO) 
 Nitric oxide functions as a weak oxidant as well as an antioxidant under 
physiological conditions (up to 100nM).  Moreover, it plays a role of vasodilation and 
membrane stability in vascular endothelium.  Acetylcholine-induced relaxation of rabbit 
aortic strips is induced by endothelium-derived relaxing factor (EDRF) (Furchgott and 
Zawadzki, 1980; Furchgott, 1983). Palmer et al. 1987 and Ignarro et al. 1987 discovered 
that EDRF is the free radical NO. Thus, the vascular relaxation by EDRF is actually due 
to NO. mediated by .OH (Kooy and Royall, 1994; Prasad and Bharadwaj, 1996). Nitric 
oxide is produced by stimulated macrophages and endothelial cells, is strongly 
correlated to inflammation, and it may play a role in the genesis of atherosclerosis.  
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Nitric oxide reacts with oxygen to form nitrogen dioxide (.NO2), which can further react 
with more .NO to form nitrogen trioxide (N2O3).  Peroxynitrate (ONOO-), a regulator of 
oxidant reactions such as nitrosation, oxidation, and nitration reactions is formed from 
the reaction of superoxide anion and nitric oxide (Beckman et al. 1990; Koppenol et al. 
1992). 
1.1.3.5 Singlet Oxygen (1O2) 
 Molecular oxygen is not a radical.  However, singlet oxygen, which is a more 
reactive form of oxygen, was first observed in 1924 and is a higher energy state 
molecular oxygen species (Wasserman, 1979).  In addition, its reactivity may be 
enhanced by specific reactions, which involve light of visible or ultraviolet wavelengths.  
The existence of molecular oxygen with a photosensitizer (photoexcitable compounds) 
reverses the spin of one of the electrons in the outer orbital thus catalyzing an oxidative 
reaction to produce singlet oxygen (Ogryzlo, 1978).  Tetrapyrroles, flavins, chlorophyll, 
hemoproteins, and nicotinamide adenine dinucleotide (NADH) are examples of 
photosensitizers that catalyze oxidative reactions in the presence of molecular oxygen to 
produce (1O2) (Ogryzlo, 1978).  Singlet oxygen may also be produced by three other 
known reactions: (1) the dismutation of (O2. -); (2) the transition metal catalyzed Haber-
Weis reaction; and (3) the oxidation of halides by H2O2 (Southorn and Powis, 1988). The 
production of singlet oxygen from phagocytic PMNLs is due to the reaction of hydrogen 
peroxide and hypochlorite (OCl) ions under the enzymatic influence of 
myeloperoxidase.  The activated PMNLs undergo a respiratory burst to release cytotoxic 
ORs (1O2, .OH, H2O2, HOCl, and O2-), which cause lipid peroxidation and protein 
oxidation resulting in cell death (Freeman and Crapo, 1982; Prasad, Kalra and 
Bharadwaj, 1993; Prasad et al. 1990; Kapoor and Prasad, 1996). 
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 As described by Prasad (2003b) the two forms of singlet oxygen are sigma and 
delta.  Sigma singlet oxygen has a short half-life and is more reactive in comparison to 
delta singlet oxygen.  On the other hand, delta singlet oxygen has a longer half-life and 
increases lipid membrane peroxidation (Southorn and Powis, 1988).  Many studies have 
demonstrated that singlet oxygen is a crucial intermediate species in the detrimental 
oxidation of biological molecules.  Specifically, it has been shown that it may react with 
many different biological molecules such as proteins, lipids and DNA and is involved in 
several disease processes including heart disease (Halliwell and Gutteridge, 1982). 
1.1.4 Important Radicals and Atherosclerosis 
1.1.4.1 Hydrogen Peroxide (H2O2) 
 Prasad (2003b) gave an account of the oxidant activity of hydrogen peroxide.  
Hydrogen peroxide is a strong, lipophilic (soluble in cell membranes) oxidant constantly 
formed primarily from enzymatic reactions of microsomes, peroxysomes and 
mitochondria.  The dismutation of the O2.- is catalyzed by the enzyme superoxide 
dismutase (SOD) to produce H2O2 in plant and animal cells.  Cellular antioxidant 
activity is demonstrated by the conversion of H2O2 →H2O + O2 and is catalyzed by the 
enzymes catalase or glutathione peroxidase (Freeman and Crapo, 1982; Prasad, Kalra 
and Bharadwaj, 1993; Prasad et al. 1990; Kapoor and Prasad, 1996). 
1.1.4.2 Hypochlorous Acid and Halogenated Amines   
 Hypochlorous acid (HOCl) and halogenated amines are not oxygen free radicals. 
They are, however, extremely strong oxidants.  In addition, neutrophil phagocytosis 
induces the production of hydroxyl radicals through a reaction where myeloperoxidase 
and Cl- are the major participants.  Hypochlorous acid is 100 times more reactive than 
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O2- or H2O2.   Moreover, it forms hydroxyl radicals as in the following reaction (Freeman 
and Crapo, 1982; Prasad, Kalra and Bharadwaj, 1993; Prasad et al. 1990; Kapoor and 
Prasad, 1996): 
     
 
                                     O2-  +  HOCl → .OH + O2 + Cl-                                                            (1) 
 
 
 
1.1.4.3 Peroxyl Radicals (ROO.) 
                                      
 Peroxyl radicals have a short half-life of nanoseconds, are produced from 
hydroxyl radical reactions with lipids, proteins, nucleotide bases and carbohydrates, 
causing cellular damage as outlined by Prasad (2003b).  However, they are less reactive 
than hydroxyl radicals (Southorn and Powis, 1988). 
1.1.5 Sources of Oxygen Radicals 
 ORs are produced under physiological and pathophysiological conditions 
throughout the body.    
1.1.5.1 Mitochondria 
 The primary location for O2- formation is the mitochondrial ubiquinone-
cytochrome b region of the electron transport chain.  In this univalent process, oxygen is 
reduced to O2- and receives one electron at a time (Southorn and Powis, 1988).  Under 
physiological conditions only 5% of the inhaled oxygen is metabolized via a univalent 
process into highly reactive ORs (Fridovich, 1978).  Yet, a tetravalent pathway 
producing no reactive oxygen species metabolizes the other 95%.  The production of 
H2O2 (formed from the dismutation of O2-) is via the Fenton reaction: 
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 (Fe2+ + H2O2 → Fe3+ + .OH + OH-) (1.1) 
 
and or the two part Haber-Weiss reaction:  
         (Fe3+ + O2- → Fe2+ + O2, Fe2+ + H2O2 → Fe3+ + .OH + OH- ) (1.2) 
  
resulting in the formation of hydroxyl radicals and hypochlorous acid (HOCL) all of 
which may occur in the mitochondria (Fridovich, 1978).  
1.1.5.2 Polymorphonuclear Leukocytes (PMNL’s) 
 Polymorphonuclear leukocytes contain the NADPH oxidase system, which is a 
membrane bound flavoprotein complex that functions as an electron transport chain.  
The NADPH oxidase system is quiescent in uninduced PMNLs.  However, upon PMNL 
receptor stimulation by specific ligands (activated complement, N-formyl- Met-Leu-Phe, 
immune complexes, and LTB4) this system catalyzes the reduction of molecular oxygen 
to superoxide anion through the following reaction: 
                                                    
                                                         NADPH 
                         2O2 + NADPH        oxidase        2O2- + NADP+ + H+                                (1.3) 
                                                                                      
 
The NADPH in this reaction originates from the pentose phosphate pathway 
(Freeman and Crapo, 1982).  In addition, the dismutation of O2- to H2O2 provides a key 
component for the synthesis of hypophalous acid (a potent oxidizing agent).  According 
to Kapoor and Prasad (1996), azurophilic granules, located within the PMNL contain 
myeloperoxidase (MPO), which is released into the phagocytic vacuole upon excitation 
of PMNLs.  Myeloperoxidase catalyzes the oxidation of halides including: chloride    
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(Cl-), bromide (Br-) and iodide (I-) to their related hypophalous acids.  HOCl is the most 
potent and abundant hypophalous acid and it is produced primarily by PMNLs.  HOCl 
can induce the chlorination of an abundance of oxidizing species such as endogenous 
and exogenous amino acids, amines, thioesters and aromatic carbon group (Pattanaik 
and Prasad, 1998; Prasad et al. 1990).  The enzyme substrate complex (MPO + H2O) 
oxidizes Cl- by the following reaction (Fantone and Ward, 1982; Freeman and Crapo, 
1982; Prasad et al. 1993; Prasad et al. 1990; Kapoor and Prasad, 1996): 
 
                             H2O2 + Cl- + H+ → HOCl + H2O                                         (1.3) 
  
 1.1.5.3 Enzymes 
 Prasad (2003b) delineated the enzymatic sources of ORs. Under physiological 
conditions 80% of the metabolized molecular oxygen is transformed into H2O2 through a 
divalent reaction.  However, 20% is transformed into superoxide anions through 
univalent reduction.  Xanthine oxidase and aldehyde oxidase are important enzymes that 
produce ORs from the metabolism of O2 during ischemic tissue injuries (Engerson et al. 
1987; McCord and Roy, 1982; McCord, 1985) 
1.1.5.4 Xanthine Oxidase and Ischemia 
 As specified by Prasad (2003b) the biochemical reactions that occur during 
ischemia induce the formation of ORs.  In non-ischemic tissue, xanthine dehydrogenase 
is an enzyme that is responsible for catalyzing the reduction of NAD+ to NADH without 
the production of any ORs.  However, during myocardial ischemia there are increases of 
xanthine and xanthine oxidase, which could lead to the formation of oxygen radicals 
(Jennings and Reimer, 1982; Chambers et al. 1985). Specifically, during ischemia-
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reperfusion xanthine dehydrogenase is transformed into xanthine oxidase by proteases 
and sulfhydryl group oxidation.   As described by Prasad (2003b) ischemic induced 
adenosine triphosphate (ATP) catabolism to adenine nucleotides (adenosine diphosphate 
{ADP}, adenosine monophosphate {AMP}, inosine) result in hypoxanthine and 
xanthine formation (McCord, 1985; McCord et al. 1985).  The combination of xanthine 
and xanthine oxidase in the presence of molecular oxygen produces the superoxide 
anion and hydrogen peroxide in the following reaction (Engerson et al. 1987; McCord 
and Roy, 1982; Fantone and Ward, 1982): 
                                                  xanthine 
                    Xanthine + O2                  O2-   + H2O2 + uric acid                            (1.4) 
                                       oxidase 
 
Vanden (1980) outlined that the decrease in pH during ischemia stimulates 
phospholipase A2 which would increase the production of arachidonic acid from 
membrane phospholipids and synthesis of prostaglandins and leukotrienes.  Moreover, 
oxygen radicals are formed during the synthesis of prostaglandins and leukotrienes 
(Panganamala et al. 1976: Murota et al. 1990).  It has been shown by Rao et al. (1983) 
that ischemia without reperfusion may produce moderate quantities of ORs from oxygen 
located within the lipid bilayer of cell membranes.  However, the burst of OR generation 
is not observed until reperfusion is strengthened by direct and indirect evidence.  The 
direct evidence has been demonstrated by electron spectroscopy of serum levels of ORs 
obtained prior to, and after reperfusion of myocardial tissue, which showed that ORs are 
generated to a limited extent during ischemia, but an increase in OR production is 
observed in the beginning period of reperfusion followed by a decrease in production for 
many hours afterwards (Zweier et al. 1987; Bolli et al. 1989).  Similarly, the indirect 
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demonstrative support for the reperfusion oxidative burst may be evidenced by 
numerous studies, which show that inhibitors or scavengers of ORs and anti-neutrophil 
agents administered during reperfusion, attenuated serum levels of OR’s (Simpson et al. 
1988; Barroso-Aranda et al. 1988; Barroso-Aranda and Schmidt-Schonobein, 1989; 
Kapoor and Prasad, 1996).  Furthermore, endogenous antioxidants such as SOD, 
catalase, glutathione peroxidase and glutathione are depleted, thus decreasing the 
inherent myocardial antioxidant defense mechanisms.  Consequently, ischemia promotes 
the biochemical circumstances for tissue damage due to OR production (Kapoor and 
Prasad, 1994).   
1.1.5.5 Arachidonic Acid 
 The production of arachidonic acid by phospholipases from cell membrane 
phospholipids and its subsequent metabolism diverges into two distinct pathways.  The 
lipoxygenase pathway producing leukotrienes and the cyclooxygenase pathway forming 
prostaglandins both generate ORs.  Specifically, during the transformation from 
prostaglandin G2 (PGG2) to prostaglandin H2 (PGH2), and from PGH2 to thromboxane A2 
(TxA2), OH- and O2-   are produced.  Likewise, OH- is produced from the lipoxygenase 
pathway of arachidonic acid metabolism (Kontos et al. 1980; Salvador et al. 1977).    
1.1.5.6 Other Sources of Oxygen Radicals   
 According to Prasad (2003b) there are various other sources of OR production 
such as the auto-oxidation of small molecules (catecholamines, flavins, hydroquinones 
and thiols) and sites such as the endoplasmic reticulum, nuclear membrane, 
macrophages and peroxisomes (Freeman and Crapo, 1982; Muller and Sies, 1987). 
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1.1.6 Oxygen Radicals and Cellular Membrane Damage 
 Prasad (2003b) detailed that oxygen free radicals with their differing reactivities 
not only generate local oxidizing effects, but also produce damaging pathological 
repercussions at regions away from the original area of production.  In addition, ORs 
have the ability to initiate and propagate free radical chain reactions that can damage 
many biological substrates (Rice-Evans and Baurdon, 1993; Southorn and Powis, 1988).  
Even though hydroxyl radicals have a half-life of nanoseconds it forms toxic products 
that can migrate to great distances to cause lipid peroxidation to vulnerable 
polyunsaturated fatty acids (PUFAs) in plasma membranes and organelles (Southorn and 
Powis, 1988).  The chain reaction and propagation of lipid peroxidation by OH – and 
probably singlet oxygen is due to their ability to attack double bonds of PUFAs in cell 
membranes as long as oxygen stores and unoxidized fatty acid chains are accessible.  
The resultant bond modification forms conjugated dienes, which react with more O2 to 
produce peroxyl radicals, lipid radicals (L.), and lipid hydroperoxides (LOOH) all of 
which can continue chain propagation (Rice-Evans and Baurdon, 1993).  However, the 
discontinuance of propagation may be caused by antioxidants such as alpha tocopherol, 
which scavenge peroxyl radicals in the presence of vitamin C (Rice-Evans and Baurdon, 
1993).  The metabolites formed from lipid peroxidation are alkanals (MDA), alkenals 
(4-hydroxynonenal) and alkanes.  Intracellular and plasma membrane injury can be due 
to MDA’s ability to induce cross-linking of structural proteins, enzymes, DNA, RNA 
and phospholipids.  In addition, MDA changes membrane permeability, ion transport, 
alters LDL degradation, causes loss of PUFAs, is mutagenic, cytotoxic and carcinogenic 
(Rice-Evans and Baurdon, 1993; Freeman and Crapo, 1982).  An increase in MDA 
levels implies an increased level of oxygen radicals, which may be caused by an 
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increased production of ORs and or decreased antioxidant reserve. An increased 
formation of ORs may be through sources such as xanthine-xanthine oxidase system, 
auto-oxidation of catecholamines and homocysteine, prostaglandin synthesis and PMNL 
stimulation (Prasad et al. 1996).   
1.1.7 Homocysteine and Oxygen Radicals 
 The oxidative hypothesis of atherosclerosis requires oxidative damage as a 
prerequisite for the development of atherosclerosis (Henriksen et al. 1981).  
Homocysteine may promote atherosclerosis by damaging endothelial cells by auto-
oxidation leading to the production of oxygen radicals (Welch et al. 1996).  The free 
sulfhydryl group of homocysteine expresses strong redox properties allowing 
homocysteine to react with another homocysteine molecule or with ferric or cupric ions 
to form disulfide, hydrogen peroxide, oxygen radicals and homocysteine radicals 
(homocysteine thiolactate) (Olszewski and McCully, 1993; Welch et al. 1996). In 
addition, homocysteine may also generate oxygen radicals by forming a mixed disulfide 
with other sulfhydryl containing proteins through a similar oxidation mechanism.  
Vascular endothelial injury has also been demonstrated by observing homocysteine 
auto-oxidation to cytotoxic superoxide anion, hydrogen peroxide and hydroxyl radicals 
(Starkebaum and Harlan, 1986; Welch et al. 1996; Hultberg et al. 1995; Misra, 1974; 
Rowley and Halliwell, 1982).  Impaired endothelial function could be due to 
homocysteine oxidation where the generated oxygen radicals induce lipid peroxidation 
in circulating lipoproteins and in the cell membranes (Heinecke et al. 1987; Tsai et al. 
1994).  As outlined by Prasad (1999) the oxidation of LDL is a critical step in the 
genesis of atherosclerotic lesion.  The superoxide anion formed by homocysteine auto-
oxidation could cause vascular injury by inducing the oxidation of LDL (Heinecke et al. 
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1987).  As described by Prasad (1999) numerous studies have correlated thiol-containing 
amino acids like homocysteine in the presence of cupric or ferric ions with increased 
oxidation of LDL (Heinecke et al. 1984; Heinecke et al. 1987; Parthasarathy, 1987).  
Moreover, homocysteine-mediated oxidation of LDL may generate lipid products that 
could stimulate platelet activation and the liberation of growth factors may induce 
smooth muscle proliferation and vascular hypertrophy (Tsai et al. 1994).  
1.1.7.1 Homocysteine and Vascular Dysfunction 
 Endothelial injury is a requirement for the response to injury hypothesis of 
atherosclerosis (Ross, 1993).  Homocysteine causes endothelial damage at several levels.  
Numerous studies have implicated that the cytotoxic effects of homocysteine on 
endothelial cells grown in tissue culture may be responsible for endothelial dysfunction 
and the genesis of atherosclerosis (Blundell et al. 1996; and Jones et al. 1994).  Lentz et 
al. (1996) demonstrated that monkeys that were fed a diet that effectuated moderate 
hyperhomocysteinemia experienced an increase in vascular dysfunction analogous to 
that observed in atherosclerotic monkeys.  Similarly, Harker et al. (1976), upon studying 
baboons that were administered uninterrupted intravenous infusions of homocysteine, 
concluded that homocysteine was a causative agent for the development of patchy 
vascular endothelial injury and intimal smooth muscle cell lesions which correlated to 
the early atherosclerotic fatty streak lesion observed in humans.  
1.1.7.2 Homocysteine and Atherosclerosis 
According to Ross (1986) the response to injury hypothesis of atherosclerosis 
requires endothelial dysfunction/damage for the progression of atherosclerosis.  
Homocysteine-induced damage is primarily due to its toxicity to endothelial cells 
(Blundell et al. 1996; Jones et al. 1994; Wall et al. 1980; Harker et al. 1974; Starkebaum 
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and Harlan 1986; Weimann et al. 1980).  The toxicity to endothelial cells created by 
homocysteine may be due to homocysteine’s formation of oxygen radicals (Blundell et 
al. 1996; Jones et al. 1994; Wall et al. 1980; Harker et al. 1974; Starkebaum and Harlan 
1986; Weimann et al. 1980).  Jones et al. (1994), demonstrated that homocysteine 
generated oxygen free radicals by observing the toxic effects of homocysteine 
independently and in the presence of Cu2+, and their correlation with increased lipid 
peroxidation, which was inhibited by catalase and attenuated by desferal.  Oxygen 
radicals have been shown to cause endothelial injury (Weis et al. 1981; Sacks et al. 
1978; Crapo, 1986; Kapoor and Prasad, 1994).  The oxidative hypothesis of 
atherosclerosis is based upon oxidative stress induced endothelial injury (Henriksen et 
al. 1981).    
The endothelial cell cytotoxicity induced by homocysteine may be related to its 
ability to produce ORs (Jones et al. 1994; Crapo, 1986).  Endothelial injury by 
superoxide anions, hydroxyl radicals, hydrogen peroxide and homocysteine radicals is 
produced when the sulfhydryl group of homocysteine is reduced by copper or iron ions 
(transition metals) (Olszewski and McCully, 1993). Moreover, in cultured cell mediums, 
which have the presence of transition metals, reduced homocysteine is oxidized by thiols 
to generate toxic ORs (Wall et al. 1980).  Active endothelial cells contain the enzymes 
necessary for homocysteine metabolism (Anderson et al. 1995).  Consequently, auto-
oxidation of homocysteine in plasma generates ORs, mixed disulfides, and 
homocysteine thiolactate (a by-product of homocysteine oxidation) (Anderson et al. 
1995).  Homocysteine thiolactate (also termed homocysteine thiolactone) has also been 
postulated to cause endothelial injury by mediating the oxidation of LDL (Heinecke et 
al. 1987).  According to Prasad (1999), macrophage and smooth muscle foam cell 
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formation is induced by the incorporation of LDL with homocysteine thiolactate 
(Naruszewicz et al. 1994).  In addition, oxidized LDL and oxygen radicals have been 
associated in the genesis of hypercholesterolemic atherosclerosis (Steinberg, 1991; 
Prasad and Kalra, 1993; Prasad et al. 1994; Prasad et al. 1997; Prasad et al. 1998).  The 
production and accumulation of immobile lipid laden foam cells in the vascular wall is 
central to the genesis of ROS and the atherosclerotic fatty streak lesion (atheromatous 
plaques) (Schwartz et al. 1993).  The chemotaxis of monocytes to the area of injury is 
under the influence of endothelial derived MCP-1.  Homocysteine has been shown to 
increase the expression of MCP-1 in human aortic endothelium (McCully, 1994).  Thus, 
an increase of the transmigration of monocytes to the area of injury may accelerate the 
development of the atherosclerotic fatty streak lesion.  Finally, homocysteine thiolactate 
may cause damage to oxidative metabolism in a microenvironment, which would induce 
overproduction of ORs that cause endothelial injury (McCully, 1994).  Particularly, in 
resting cells the prevention of mitochondrial free radical damage is mediated by the 
conversion of homocysteine thiolactone to thioretinaco ozonide. Thioretinaco ozonide 
functions as an electron acceptor in molecular oxygen metabolism and as the binding 
site for ATP synthesis by mitochondria. During cell division methionine is converted to 
homocysteine thiolactone, which in turn converts thioretinaco ozonide to thioco.  Thioco 
increases OR generation, and decreases cellular defensive antioxidants glutathione and 
ascorbate.  Thus, an impairment of homocysteine thiolactone metabolism results in a 
attenuation of the protective effect of thioretinaco ozonide and may lead to derangement 
of oxidative phosphorylation with keratinization, squamous metaplasia, and dysplasia of 
the endothelium and smooth muscle (Prasad, 1999; Fiddian-Green, 2002; McCully, 
1993). 
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Homocysteine may also induce atherosclerosis by damaging endothelial cells 
through decreasing the plasma concentrations of antioxidants.  According to Toboreck et 
al. (1995), methionine-induced atherosclerotic rabbits exhibited a decrease in the activity 
of antioxidant enzymes such as: superoxide dismutase (SOD), catalase, and glutathione 
peroxidase (GSH-Px).  However, in red blood cells the concentration of SOD increased, 
catalase was unchanged, and GSH-Px was attenuated.  Additionally, the activity of aortic 
antioxidant enzymes increased with this treatment. Thus, the variations in antioxidant 
status were correlated with aortic atherosclerosis.  The data suggests that methionine-
induced atherosclerosis may be related to oxidative stress.  Moreover, this treatment may 
also increase plasma and aortic malondialdehyde, which increases membrane 
permeability with a loss of membrane integrity (Toboreck et al. 1995).  Hultberg et al. 
(1995) described the mechanism of endothelial cell damage by the metabolism of 
homocysteine.  As described by Prasad (1999) hyperhomocysteinemia may cause an 
increase in intracellular reduced homocysteine that may enter the transulfuration 
pathway of homocysteine metabolism, producing cysteine, glutathione, and sulfate 
(Hultberg et al. 1995).  The imbalance created by elevated levels of reduced 
homocysteine causes a ratio favoring decreased glutathione and NAD+ (Blundell et al. 
1996).  This imbalance may induce a decrease in antioxidant reserve, which would 
increase the likelihood of lipid peroxidation and endothelial damage leading to the 
genesis of atherosclerosis (Steinberg, 1992; Prasad, 1994).    
1.1.7.3 Homocysteine and CAD 
 Wilcken D and Wilcken B (1976) published the first report, correlating patients 
with coronary artery disease with abnormal homocysteine metabolism.  The increase in 
studies in the 1990s relating homocysteine to coronary artery disease is significant 
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(Boushey et al. 1995; Mayer et al. 1996; Angeline et al. 2005; Clarke et al. 1991; 
Stampfer et al. 1992; Glueck et al. 1995).  Stampfer et al. (1992) described an 
association between homocysteine levels and myocardial infarction.  They observed, 
after correction for other conventional risk factors, that men with plasma homocysteine 
levels 12% above the upper limit of the normal range experienced a three-fold increase 
in the risk of a myocardial infarction as compared with those with lower levels.  In 
another study conducted by Alfthan et al. (1994) it was observed that baseline 
homocysteine concentrations were correlated with the evolution of myocardial infarction 
and death during the follow-up period.  In addition, Boushey et al. (1995) in a 
retrospective study of 4000 patients came to the conclusion that homocysteine is an 
independent risk factor for coronary artery disease by observing that 10% of the risk of 
coronary artery disease in the general population may be caused by homocysteine.  They 
also determined that an increase of the plasma homocysteine concentration of 5μmol/L 
raises the risk of coronary artery disease to a similar level as that of an increase of 0.52 
μmol/ L cholesterol concentration.  However, a study conducted by Nygard et al. (1997), 
which consisted of 587 patients with coronary artery disease, concluded that total plasma 
homocysteine concentration had a weak correlation with the degree of coronary artery 
disease.  On the other hand, they discovered that there was a firm relationship between 
homocysteine concentration and overall mortality, particularly when the homocysteine 
concentration was above 15 µmol/ L.   
1.1.7.4 Homocysteine and Smooth Muscle   
 Two notable hallmarks of atherosclerosis are smooth muscle cell proliferation 
and migration and collagen deposition.  The relationship of homocysteine to increases in 
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smooth muscle cell proliferation has been investigated.  According to Majors et al. 
(1997) homocysteine enhances cultured arterial smooth muscle cell density and 
stimulates collagen production.  Furthermore, homocysteine thiolactate, a by-product of 
homocysteine oxidation, has been implicated in fibrosis and proliferation of smooth 
muscle (McCully, 1993).   In addition, the effect of homocysteine on the growth of both 
vascular smooth muscle and endothelial cells at physiological concentrations 
demonstrated that the incorporation of 0.1mM of homocysteine produced a 25% 
increase in DNA synthesis in rat aortic smooth muscle cells (RASMC).  Similarly, 
homocysteine concentration of 1mM increased DNA synthesis by 4.5 times in RASMC 
and analogous increases in DNA synthesis were observed with homocysteine 
assimilation into human aortic smooth muscle cells.  However, homocysteine attenuated 
DNA synthesis in human umbilical vein endothelial cells (HUVEC) (Tsai et al. 1994).   
According to Lubec et al. (1996) and Tsai et al. (1994) homocysteine stimulates the 
mRNA of cyclins (regulators of cell cycles) necessary for the return of inactive cells into 
the cell cycle.    Specifically, cyclin D1 and cyclin A induced by growth factors or serum 
function as growth regulators during the early G1 phase and S and G2/M phase of the cell 
cycle respectively (Tsai, 1996).  Therefore, the interactions of homocysteine and growth 
factors or serum induce the replication of vascular smooth muscle cells lining the blood 
vessels and facilitate the mechanism for homocysteine-induced atherosclerosis (Tsai et 
al. 1994; Tsai, 1996).  
1.1.7.5 Homocysteine and Nitric Oxide 
   Homocysteine-induced endothelial injury and dysfunction may predispose the 
endothelium to decrease the synthesis and release of nitric oxide (Wall et al. 1980; 
Stamler et al. 1993). The functions of the endothelial-derived relaxing factor, nitric 
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oxide include: (1) regulation of the following; endothelial–leukocyte interactions, 
smooth muscle proliferation, vascular tone (via vasodilation); and (2) inhibition of 
platelet adhesion and aggregation (Luscher et al. 1996).  Homocysteine chemically 
reacts with NO in the presence of water (nitrosation) to produce S-nitroso-homocysteine, 
which is similar to NO in that it inhibits platelet aggregation and causes vasodilation but 
does not produce H2O2.  The nitrosation of homocysteine has been suggested to act as a 
protective mechanism to offset homocysteine’s deleterious effects.  Nevertheless, the 
time and concentration of tissue exposed to homocysteine likely determines its effect on 
nitric oxide production.  For instance, in a dose dependent approach, the early 
consequence of exposure of bovine aortic endothelial cells to homocysteine was an 
increase in NO synthesis (Upchurch et al. 1997).  However, 15 minutes of exposure of 
bovine aortic endothelial cells to homocysteine resulted in the production of NO and S-
nitroso-homocysteine (Upchurch et al. 1997).  Even further, chronic exposure and 
elevated concentrations of homocysteine attenuated NO formation (Stamler et al. 1993; 
Upchurch et al. 1996).  Therefore, increasing levels of homocysteine may damage 
endothelium, indirectly induce atherosclerosis by decreasing NO bioavailability, and 
diminish the protective effects of S-nitroso-homocysteine (Stamler et al. 1993; Upchurch 
et al. 1996; Hultberg et al. 1995; Stuhlinger et al. 2001). 
1.1.7.6 Homocysteine and Thrombosis 
 Homocysteine-induced thrombosis may be due to its procoagulant activity as 
well as its ability to attenuate the anticoagulation mechanism (Lee and Prasad, 2002).  
The endothelial synthesis of clotting factors helps to maintain the delicate balance 
between procoagulant and anticoagulant pathways that is crucial to vascular homeostasis 
(Thambyrajah and Townsend, 2000; Thrambyrajah et al. 2001).  The endothelium 
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creates an antithrombogenic surface through the following mechanisms: (1) inhibition of 
platelet activation by ecto–ADPase, prostacyclin, and NO; (2) production of 
plasminogen activators (limit plug formation and fibrin deposition) and; (3) regulation of 
antithrombin III (heparin sulfate), thrombomodulin, and protein C activity (Rogers, 
1988).  The mechanisms of accelerated vascular atherothrombosis due to 
hyperhomocysteinemia may be multi-factorial.  Platelet dysfunction, coagulation 
abnormalities, and endothelial impairment (through the release of ROS) are possibly the 
results of elevated plasma homocysteine concentrations (Lee and Prasad, 2002). 
1.1.7.7 Homocysteine and Platelets 
 Homocysteine-induced endothelial injury and dysfunction exposes the 
subendothelial matrix, which stimulates platelet activation and thrombus formation 
(Harker et al. 1976).  In addition, platelet adhesiveness may be increased in 
hyperhomocysteinemia due to a modification of platelet arachidonic acid metabolism 
(Shattil et al. 1975).  Arachidonic acid metabolism through the cycloxygenase pathway 
produces the proaggregant vasoconstrictor thromboxane A2 (TxA2) (Di Minno et al. 
1993).  According to Durand et al. (1997) rats in which hyperhomocysteinemia were 
induced by folate deficiency developed an increase in methionine concentrations, TxA2 
synthesis, and macrophage factor activity.  Since elevated plasma homocysteine 
concentrations may cause an increase in platelet TxA2 synthesis with concurrent 
increased platelet adhesion, then this may strongly contribute to the prothrombotic effect 
observed in hyperhomocysteinemia.  Antiplatelet therapy administered to baboons with 
hyperhomocysteinemia exhibited a decrease in intimal lesion expression implying that 
platelets are involved in smooth muscle proliferation (Harker et al. 1976).  On the other 
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hand, Di Minno et al. (1993) reported that in in-vitro platelet function tests there were no 
significant differences between homocysteinuric patients and healthy controls. 
1.1.7.8 Homocysteine and Procoagulant Factors 
   Factor V is an important cofactor in the common pathway of the coagulation 
cascade.  Homocysteine induces a protease endothelial cell activator of factor V, and 
provides a pathway for the augmentation of coagulation in the absence of thrombin 
(Rogers and Kane, 1986).  They reported that subsequent to administration of 0.5 
mmol.1-1 of homocysteine, human umbilical vein endothelial cells demonstrated an 
increase in Factor V activity.  Moreover, after administration of homocysteine at levels 
of 0.3-0.6 mmol.1-1, the activity and transcription of tissue factor is increased (Fryer et 
al. 1993).  Homocysteine also activates factor XII of the intrinsic pathway of the 
coagulation cascade, and inhibits the activity of thrombomodulin.   Thrombomodulin is 
an endothelial surface glycoprotein that binds with thrombin to activate protein C.  
Activated protein C causes the inhibition of factors Va, and VIIIa (Bertina et al. 1994).  
Homocysteine influences thrombomodulin by attenuating its surface expression on 
endothelial cells. It has been demonstrated by Lentz and Sadler (1991) that 
homocysteine precisely and irreversibly deactivates thrombomodulin and protein C.   In 
addition, a study involving the in-vivo thoracic aorta of monkeys with diet-induced 
hyperhomocysteinemia reported a thrombomodulin dependent protein C activation 
decrease by 35% compared to controls (Lentz et al. 1996). Therefore, the ability of 
homocysteine to inhibit thrombomodulin and thus protein C activity may have the effect 
of endothelial thrombus formation (Lee and Prasad, 2002; Griffin et al. 1995). 
Homocysteine is also engaged in the deactivation of fibrinolysis by the inhibition 
of transplasminogen activator (t-PA) binding to human endothelial cells.  
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Transplasminogen activator is responsible for the conversion of plasminogen to plasmin, 
which lyses fibrin (Hajjar, 1993). Finally, homocysteine blocks the expression of the 
anticoagulant heparin sulfate, which binds to thrombin and causes its deactivation (Port 
et al. 1996).  Homocysteine-induced inhibition of heparin sulfate is accomplished by the 
production of hydrogen peroxide (Nishinaga et al. 1993).  Thus, by inhibiting heparin 
sulfate homocysteine contributes to thrombus formation. 
1.1.8 Percutaneous Coronary Intervention (PCI) 
 Percutaneous coronary intervention is a medical procedure in which a high-grade 
coronary stenosis (plaque) is dilated with a balloon tipped catheter system (percutaneous 
coronary angioplasty {PTCA}), and, or supported by metal scaffolds (stents) to 
diminish, and, or prevent the ischemic effects of coronary atherosclerosis (Serruys et al. 
1994; Sigwart et al. 1987).  Inflation of the balloon tipped catheter to a desired 
atmospheric pressure results in intra-luminal radial forces. These forces produce plaque 
compression.  However, the primary change in lumen geometry is caused by endothelial 
denudation, fracture and separation of plaque from the underlying medial and adventitial 
layers (Fischman et al. 1994).   Although balloon inflation provides an increased lumen 
for blood flow, the endothelial injury that results may induce two important adverse 
outcomes of PCI – acute vessel closure and restenosis.  The angiographic restenosis rate 
for balloon PCI alone is approximately 30- 40 %; however the clinical restenosis rate is 
20 to 30% (Bengtson et al. 1990; Ruygrok et al. 2001; Cannan et al. 1999).  Acute vessel 
closure is usually a result of vessel dissection, and, or thrombus formation in about three 
to five percent of cases and it typically occurs within the first twenty-four hours of the 
procedure (O’ Meara and Dehmer, 1997).  The clinical events produced from acute 
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vessel closure are myocardial infarction, emergency coronary artery bypass surgery, and 
death (O’ Meara and Dehmer, 1997). 
1.1.8.1 PCI and Coronary Restenosis 
 Restenosis is an adverse outcome following balloon angioplasty and stenting for 
atherosclerosis in which there is a re-narrowing of the artery.  The elevated incidence of 
restenosis following PCI progressively limits long term benefits of the procedure.  
Restenosis is most likely the result of physical damage to the endothelial and subintimal 
layers of the vessel from the PCI procedure itself. Consequently, the artery attempts to 
repair itself through the stimulation of smooth muscle cell migration from the media of 
the vessel wall into the subintimal region where they proliferate (Serruys et al. 1994; 
Sigwart et al. 1987).   The inability of the smooth muscle cells to regulate their own 
growth effectively results in neointimal hyperplasia, and vascular remodeling that may 
eventually hinder adequate blood flow due to luminal size reduction ultimately inducing 
major cardiac events (MACE) i.e. myocardial ischemia, infarction, thrombosis, or death 
(Serruys et al. 1991; Serruys et al. 1994; Sigwart et al. 1987). The two major categories 
of restenosis for balloon angioplasty are angiographic restenosis, which is defined as a 
50% reduction of luminal diameter at follow-up angiography, which is 25 to 50% of all 
cases, and clinical restenosis, which is defined as recurrent angina (chest discomfort), 
which occurs in 20 to 30% of patients (Hansrani, 2002).  Clinical restenosis usually 
occurs within the first six to nine months following the procedure (Hansraniet al. 2002).  
1.1.8.2 Coronary Stenting 
 Coronary stents are metallic mesh conduits which are implanted over the area of 
stenosis and deployed by balloon inflation to function as a structure to maintain the 
lumen of the vessel wall with the expectation of circumventing abrupt closure and 
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restenosis (Schatz, 1988).    Coronary stents have been utilized in over 85% of the PCIs 
since the late 1990s (Lane, 1999).  Intracoronary stents are indicated for: (1) the 
prevention of coronary restenosis; (2) the treatment of an acute myocardial infarction; 
(3) the treatment of saphenous vein graft stenosis; and (4) the prevention of acute vessel 
closure (Lane, 1999).  Clinical in-stent restenosis remains a major problem with bare 
metal stents occurring in 30- 40% of patients following PCI (Erbel et al. 1996; Cultip et 
al. 2002). 
There are two basic types of stents: bare metal (uncoated stents) and drug eluting 
stents (DES).  Drug eluting stents are impregnated with a polymeric drug coating which 
has anti-inflammatory and anti-proliferative actions through continuous local release 
(Schwartz et al. 2004).  The two major drug eluting stents, the Taxus (Boston Scientific), 
and the Cypher (Johnson and Johnson) are coated with paclitaxel and sirolimus 
respectively (Herrmann, 2003; Goy et al. 2005).   
1.1.8.3 Drug Eluting Stents 
Paclitaxel Drug Eluting Stents 
Paclitaxel is a drug which decreases cell division and migration through inhibition of 
microtubule formation (Herrmann, 2003).  Studies have been conducted on the release 
formulations of paclitaxel-eluting stents compared to bare metal stents in humans with 
low risk coronary lesions undergoing PCI.  The TAXUS II trial used two different 
paclitaxel release formulations to show the safety and efficacy in a large group of 
patients. The stents were coated with a polymer designed to control paclitaxel release 
with a fundamental burst phase over the initial 48 hours following implantation, and 
then a low level release for ten days. The low-level release formulation was either slow 
release, where 90% of the total dose loaded (paclitaxel eluting stents were coated with a 
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dose of 1µg/mm2) remained sequestered within the polymer formulation or moderate 
release where 75% remained sequestered within the polymer formulation.  Coronary 
angiography after six months revealed that the biphasic polymer managed delivery of 
low levels of paclitaxel produced substantial decreases in neointimal proliferation as 
compared to controls (Colombo et al. 2003).  However, other studies measuring the 
effects of paclitaxel delivery using different dosing and delivery systems revealed that 
the ability to deliver large quantities of paclitaxel through acrylate polymer coatings 
were correlated with high incidences of acute, subacute, and late in-stent thrombosis 
(SCORE Trial; Sousa et al. 2003).  In addition, paclitaxel release from stents with 
nonpolymer-based delivery systems did not translate into patient clinical benefit (Park et 
al. 2003).   Moreover, the patients in the TAXUS II trial had low risk lesions and it is not 
clear whether a slow release formula would be applicable to high risk patients or patients 
which present with complex lesions.  Furthermore, the attenuation of restenosis has been 
demonstrated with drug eluting stents in large arteries with short lesions.  However, 
there is not a substantial body of evidence to prove a decrease in the frequency of 
clinical restenosis in patients with disease bifurcation, chronic total occlusions, 
saphenous vein graft disease, or multivessel disease (Moses et al. 2003).  
Sirolimus Eluting Stents 
 Sirolimus (rapamycin), a naturally occurring product that was discovered in a 
soil sample from Easter Island, is isolated from the species Streptomyces hygroscopicus.  
It is a lipophilic macrolide that has potent immunosuppressive effects on mammals, and 
has an impact on the care of patients with coronary artery disease because of its ability 
to inhibit vascular smooth muscle proliferation, and thus in-stent restenosis (Marx et al. 
1995; Poon et al. 1996).  The process by which sirolimus retards cell growth is related to 
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cell cycle arrest at the transition from the G1 to S phases (Poon et al. 1996; and Luo et al. 
1996).  A study in pig models revealed that systemic sirolimus administration could 
inhibit restenosis in a model of angioplasty (Gallo et al. 1998).  In addition, the 
Sirolimus-Eluting Bx Velocity Balloon- Expandable Stent utilized in a randomized 
study (RAVEL) exhibited attenuation in the frequency of in-stent restenosis (Fajadet et 
al. 2005; Windecker et al. 2005).  Moreover, the (SIRIUS) trial evaluated the frequency 
of in-stent restenosis among patients with complex coronary artery disease that had 
sirolimus coated stents implanted, and found that the restenosis rate decreased to 18 % in 
the sirolimus group compared to a 51% restenosis rate in the bare metal stent group 
(Lemos et al. 2003; Schampaert et al. 2004; Schofer et al. 2003).  However, it is not 
clear as to the duration of inhibitory effects induced by sirolimus or, whether or not there 
are subgroups of patients who are more resistant than others to therapeutic consequences 
of sirolimus (Schwartz et al. 2004; Moses et al. 2003). 
1.1.9 Homocysteine and Restenosis  
 Restenosis following successful PCI continues to be an adverse outcome of this 
procedure.  The numerous data that correlate homocysteine with the risk of the 
development, and the severity of CAD has stimulated interest in its possible function in 
restenosis (Prasad, 1999; Schnyder et al. 2002b).  Homocysteine-induced smooth muscle 
cell proliferation, loss of endothelial function, coagulation abnormalities and plasma 
lipoprotein oxidation (from OR generation) associated with atherogenesis may 
contribute to restenosis as well.  Thus the investigation of the governed release of 
intracellular homocysteine release into the plasma may provide a feasible biochemical 
marker for restenosis (Schnyder et al. 2001; Woo et al. 1997).   
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In a prospective study conducted by Schnyder et al. (2001), including 205 
patients who underwent successful PCI of at least one coronary stenosis (≥50%), plasma 
homocysteine samples were drawn between 8 and 12 hours following the procedure.  Of 
the 200 patients, 89% underwent angiography at 6 months for direct visualization of 
angiographic restenosis.  The results demonstrated that patients with plasma 
homocysteine concentrations below 9.0 μmol/ L had a restenosis rate 49% lower than 
those patients who had homocysteine levels above 9.0 μmol/ L. This research offered 
one of the initial prospective indications that plasma homocysteine concentrations 
predict restenosis following PCI in small vessels treated with balloon angioplasty alone.  
Likewise, Morita et al. (2000) conducted a case controlled study of 112 males who 
underwent successful PCI in which they measured plasma homocysteine concentration 
as a possible risk factor for coronary restenosis at follow-up angiography (3-6 months).  
They discovered that plasma homocysteine concentrations were significantly higher in 
patients who developed restenosis.  In addition, Schnyder et al. (2001) further 
investigated homocysteine in a prospective, randomized, double blind interventional trial 
to study the effect of lowering plasma homocysteine levels on restenosis following PCI.  
They administered a combination of folic acid (1mg), vitamin B12 (400 μg), and 
pyridoxine (10mg) or placebo to 205 patients for six months after successful PCI.  The 
primary and secondary end points were restenosis within six-months (determined by 
angiography), and the presence of MACE.  Their results demonstrated that treatment 
with an anti-homocysteine formula significantly attenuated homocysteine concentrations 
and the rate of restenosis following PCI.  In contrast, Bennoitt et al. (1999) performed a 
prospective trial of 222 patients who underwent PCI and were followed up clinically for 
six months.  Their findings suggested that there was no significant difference in 
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homocysteine concentrations between patients with multiple restenosis, and those 
without restenosis.  Similarly, Miner et al. (2000) conducted a small prospective study 
using follow-up angiographic data of less than six months were also unable to find a 
significant correlation between homocysteine and the development of restenosis after 
PCI.  Wong et al. (2004) performed a prospective single center observational study on 
134 patients that electively underwent their first PCI without stent implantation and 
determined that there was no association between baseline plasma homocysteine levels, 
and the rate of restenosis after six months.  Finally, it is apparent that there still exists 
much controversy on the role of homocysteine and restenosis in patients undergoing 
PCI. 
1.1.10 Oxygen Radicals and Restenosis 
The endothelial injury induced by the PCI itself can activate platelets and 
neutrophils that may produce ROS.  Reactive oxygen species formed at the site of 
damage may stimulate chain reactions of endothelial dysfunction and LDL oxidation 
leading to restenosis.  OXLDLs activate macrophages, which in turn liberate numerous 
growth factors that induce smooth muscle proliferation.  Smooth muscle cell 
proliferation, migration, and collagen accumulation are major determinants of 
neointimal growth.  Mediators of smooth muscle cell proliferation are numerous, 
including ROS (Teirstein and King, 2003; Marumo et al. 1997; Sundaresen et al. 1995).  
Smooth muscle cell proliferation and stenosis after vascular injury coincide with 
elevations in ROS (Szocs et al. 2002; Shi et al. 2001).  Reactive oxygen species have 
been implicated in growth signaling pathways and in smooth muscle cell proliferation 
(Colavitti et al. 2002; Abe and Berk, 1999; Bhunia et al. 1997).   In addition, Jacobson et 
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al. (2003) have implicated that superoxide anions are involved in neointimal 
development after vessel injury based on the administration of the neointimal inhibitor 
gpg1ds-tat (the chimeric peptide inhibitor of NAD(P)H oxidase assembly).  Moreover, 
ROS have been correlated with the development of hypercholesterolemic atherosclerosis 
(Prasad and Kalra, 1993; Prasad, 1999; Prasad, Kalra and Lee 1994; Prasad, 2005; 
Prasad, 1997b).  Tardif et al. (1997) investigated the oxidative stress produced by PCI 
with subsequent restenosis.  In a double blind randomized trial they studied whether 
drugs with antioxidant qualities attenuate the occurrence and severity of restenosis 
following angioplasty.  Their work suggested that antioxidants may have inhibited 
endothelial dysfunction, LDL oxidation, and attenuated neointimal formation all of 
which may be involved in the mechanism of restenosis.    
 The sources of oxygen radicals during PCI could be numerous including 
xanthine-xanthine oxidase, mitochondria, polymorphonuclear leukocytes, arachidonic 
acid metabolites, homocysteine and C-reactive protein (Prasad et al. 1996; McCord and 
Roy, 1982; Prasad, 1999; Misra, 1974; Kanellakis et al. 2004).  Thus, it is plausible that 
ORs may be involved in restenosis following PCI. 
1.1.11 Exercise Tolerance Testing (ETT) 
  An exercise tolerance test (ETT) evaluates myocardial function during physical 
or pharmacological exertion to examine cardiac reaction to increased demand for oxygen 
and thus offers crucial information that a normal electrocardiogram (ECG) will not 
provide (Bruce, 1956; Bengtson et al. 1990). Exercise tolerance testing has proven to be 
one of the most practical non-invasive methods of discovering latent coronary artery 
disease (Bruce, 1956; Bengtson et al. 1990).  Generally, patients with coronary lesions 
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of up to 50% obstruction in one vessel may be asymptomatic even though there may be 
a reduction in blood flow (Astrand, 1965).  Moreover, Dagenais et al. (1982) 
demonstrated that a decrease in blood flow must be at least 75% to elicit changes in the 
ECG.  Work by Bengtson et al. (1990) suggested the usefulness of this diagnostic tool 
by illustrating a positive correlation between stress tests and coronary angiograms in 200 
patients where they were able to detect lesions as low as 25%.   
 The hallmark of exercise stress testing is based on the discovery that exercise in 
patients with coronary artery disease induces ST-segment depression (Bruce, 1956; 
Bruce, 1967; Bengtson et al. 1990).  Angina, ST segment and T wave changes in the 
ECG are evidence of ischemia due to a lesion that produces a decreased blood flow in a 
coronary artery (Dagenais et al. 1982; Goldschlager et al. 1976). In patients who 
experience atypical chest pain, a maximum stress test may often establish the presence 
or absence of coronary artery disease.  In terms of assessing prognosis and severity of 
coronary artery disease, several studies have suggested that exercise tolerance testing is 
accurate in determining these parameters (Dagenais et al. 1982; Goldschlager et al. 
1976). In addition, the exercise tolerance test is instrumental in identifying recurrent 
ischemia in patients post- PCI that may be at risk for restenosis (Bengtson et al. 1990).   
1.2 HYPOTHESIS 
The long-term benefit of PCI is hampered by the possibility of restenosis of the 
treated segment, which occurs in 20-50% of patients (Nobuyoshi et al. 1988; Hirshfeld 
et al. 1991; Waller, 1989).  Intracoronary stent implantation along with balloon 
angioplasty is highly effective in the treatment of acute vessel closure (Sigwart et al. 
1987; Roubin et al. 1992; de Jaegere et al. 1993a; Fischman et al. 1994).  However, bare 
metal stents are thrombogenic, and the benefit achieved at the expense of high-risk 
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vascular complications (Schatz et al. 1991; Serruys et al. 1994; de Jaegere et al. 1993b; 
Serruys et al. 1991) must be considered.  The use of stents has significantly improved 
the outcome of PCI.  Despite major advances in PCI, in-stent restenosis remained a 
major limitation until recently.  Drug eluting stents have emerged as a very promising 
approach in preventing restenosis and improving clinical outcome (Fischman et al. 1994; 
McKeage et al. 2003; Grube et al. 2003; Gershlick et al. 2004; Waugh and Wagstaff, 
2004).  However, the possibility of restenosis exists.  In-stent restenosis is now the most 
common form of restenosis.  The incidence is between 20-40% with bare metal stents 
and less than 10% with drug eluting stents (Macaya et al. 1996; Stone et al. 2004).  Up 
to half of restenosis (20-50%) is quiescent, but it may result in myocardial ischemia as 
with symptomatic patients.  While stent based therapeutics in clinical trails have shown 
markedly reduced rates of restenosis, the scope of clinically proven anti-restenotic 
agents is still extremely limited, requiring additional strategies (Morice et al. 2002; 
Teirstein and King, 2003).   
Restenosis can be caused by numerous factors including inflammation, platelet 
mediated thrombus formation, proliferation of smooth muscle cells and vascular 
remodeling (Waller, 1989).  Smooth muscle cell proliferation, migration and collagen 
accumulation are major determinants of neointimal growth.  Mediators of smooth 
muscle cell proliferation are abundant, including ROS (Teirstein and King, 2003; 
Marumo et al. 1997; Sundaresen et al. 1995).  Smooth muscle cell proliferation and 
stenosis after vascular injury coincide with elevations in ROS (Szocs et al. 2002; Shi et 
al. 2001).  Reactive oxygen species have been demonstrated in growth signaling 
pathways and in smooth muscle cell proliferation (Colavitti et al. 2002; Abe and Berk, 
1999; Bhunia et al. 1997).  Reactive oxygen species have been suggested in the 
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development of hypercholesterolemic atherosclerosis (Prasad and Kalra, 1993; Prasad, 
1999; Prasad et al. 1994; Prasad, 2005; Prasad, 1997b; Prasad, 1998).  Antioxidants 
attenuate/ prevent the development of atherosclerosis in cholesterol-fed rabbits and in 
humans (Prasad and Kalra, 1993; Prasad, 1999; Prasad et al. 1994; Prasad, 2005; Prasad, 
1997a).  The sources of oxygen radical production during PCI could be numerous 
including xanthine-xanthine oxidase, mitochondria, polymorphonuclear leukocytes, 
arachidonic acid metabolites, homocysteine, and C reactive protein (Prasad, 1999; 
Prasad, 1997a; McCord, 1985; Prasad, 2003a; Prasad, 1999; Misra, 1974; Prasad, 2004).  
It is possible that ORs may be involved in restenosis following PCI.  In this context 
Kojoglanian et al. (2003) have demonstrated that elevated concentrations of plasma 
homocysteine are well correlated with increased risk of the development of coronary 
restenosis.  However, Koch et al. (2003) reported no association between plasma levels 
of homocysteine and restenosis. 
Based on the above background knowledge it is therefore hypothesized that 
plasma levels of homocysteine and serum levels of MDA may be predictors of 
restenosis following percutaneous coronary intervention.  
1.3 RATIONALE FOR THE STUDY 
 The relationship between pre-PCI plasma homocysteine concentrations and 
coronary restenosis following a successful PCI remains controversial.  It has been shown 
that homocysteine can cause the endothelial damage to induce atherogenesis, and 
possibly restenosis. It has also been demonstrated that the auto-oxidation of 
homocysteine produces ORs, and these reactive oxygen species may induce 
atherogenesis and perhaps restenosis.  The controversy of whether or not homocysteine 
can predict the development of restenosis may be better understood if the oxidative 
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stress produced by homocysteine and by other sources are investigated.  Perhaps the 
varying sources that produce ORs increase oxidative stress to the extent that they are 
primarily involved with the formation of coronary restenosis.   Total oxidative stress can 
be indirectly quantitated by measuring serum malondialdehyde (MDA), a lipid 
peroxidation product related to lipid membrane damage.  It is possible that pre-
procedural serum MDA and plasma homocysteine levels are elevated in patients who 
develop restenosis.  It is also plausible that high levels of homocysteine and low levels 
of MDA in post-PCI patients may show no restenosis.  This study will elucidate the 
understanding of the relationship between plasma homocysteine, serum MDA, and 
restenosis in patients following PCI.    
1.4 OBJECTIVES 
The objectives of this study are to determine: 
(1) Whether pre-procedural levels of plasma homocysteine are elevated in patients who 
develop restenosis following PCI. 
 (2) Whether pre-procedural levels of oxidative stress (MDA) are elevated in patients 
who develop post-PCI restenosis.  
(3) Which of the two (MDA or Homocysteine) is a better predictor of restenosis. 
(4) Whether plasma levels of homocysteine and, or, serum MDA levels are pre-
procedural predictors of restenosis following PCI. 
 To achieve the above objectives specific parameters were measured in the blood 
serum and plasma.  Oxidative stress was assessed by measuring lipid peroxidation 
products or malondialdehyde (MDA) in serum.  Homocysteine was measured from 
plasma samples using fluorescence polarization immunoassay technology.    
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2.0 PATIENTS AND METHODS 
2.1 PATIENT SELECTION 
 Fifty-one patients with coronary artery disease signed a consent form to 
participate in the study.  The University of Saskatchewan Biomedical Research Ethics 
Board approved the study protocol (EC # 2003-800).  The Royal University Hospital 
Ethics Committee also approved the study.  Clinical characteristics and demographics of 
the patients were obtained through direct interviews with the patients prior to the 
procedure or from patients’ files with permission.  The demographics and clinical 
characteristics are summarized in Tables 1-3.  All patients in the study met the following 
criteria: (1) patients’ with discrete denovo localized lesions in single or multiple vessels; 
(2) patients that were non-diabetic; (3) patients who experienced stable angina; (4) 
patient’s that were non-acute MI or non-acute coronary syndrome; (5) patients that were 
ambulatory and capable of performing an exercise tolerance test (ETT); and (6) patients 
that were willing to return for follow-up.  The patients were divided into two groups: 
twenty-two who developed post-PCI restenosis (group I) and twenty-nine who did not 
develop post-PCI restenosis (group II). 
 All of the patients that underwent PCI were scheduled to return for a follow-up 
ETT at two weeks and six months post-PCI or at anytime within six months if they 
developed recurrent angina. 
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2.1.1. Exercise Tolerance Test Timetable 
 The exercise tolerance test timetable for study patients was as follows: (1) two 
weeks post-PCI; (2) 6 months post-PCI; and (3) at any point within the six month 
follow-up period where the patient experienced recurrent angina. 
2.1.2 Criteria for Restenosis 
 The criteria for clinical coronary restenosis were as follows: (1) angina; (2) failed 
ETT; and (3) angina and angiographic evidence. 
2.2 METHODS 
 The most common approach for the measurement of free radical activity is to 
measure the end products of lipid peroxidation (MDA), by means of a thiobarbituric acid 
reaction (TBA Test) as described by Prasad (2001). 
2.2.1 Serum Preparation for MDA Assay 
 Serum preparation:  Seven milliliters of arterial blood was collected and 
transferred into labeled serum vacutainer tubes (EM Science, Merck KgaA, Germany).  
Blood samples were then kept refrigerated at 4 °C and left to clot at until centrifugation 
within six hours.  The blood was centrifuged at 3000 RPM for 15 minutes and serum 
was pipetted into labeled Eppendorf tubes and stored at -80°C. 
2.2.2 Materials for MDA Assay 
 The MDA standard solution consisted of (~ 97% in solution) 1, 1, 3, 3,-
tetraethoxypropane (Sigma Aldrich Canada, LTD).  A 100 µM stock solution of MDA 
was prepared by adding 6 µL of MDA standard to 250 ml of double distilled (DD) water 
in a volumetric flask. 
 The sodium lauryl sulphate solution (SDS) (8.1% w/v) was prepared by 
dissolving 8.1 g   SDS in 100 ml of DD water. 
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 Thiobarbituric acid 0.67% w/v (TBA) (Sigma Aldrich Canada) was prepared by 
dissolving 3.35 g of TBA dissolved in 50 ml of 2.0 N NaOH.  The pH was adjusted to 
5.9 with the addition of concentrated HCL, and the volume increased to 500 ml with the 
addition of DD water. 
 Glacial acetic acid (20%) was prepared in a fume hood by adding 200 ml of 
glacial acetic acid to 800 ml of DD water. 
 The pyridine/butanol solution was also prepared in a fume hood by adding 50 ml 
of pyridine to 450 ml butanol in a graduated cylinder. 
2.2.3 Method for MDA Assay 
 A 10µM working MDA standard solution was composed before assay by adding 
100µL of MDA stock solution to 900 µL of distilled water.  Ten-milliliter glass tubes 
were used to perform the assays in duplicate.  In order to zero the spectrophotometer, 
blank tubes were prepared; using 800 µL of distilled water each.  Next, standard tubes 
were prepared by adding 25 µL of the working MDA solution to 775 µL of distilled 
water to bring the total volume to 800 ml.  Consecutively, 25 µL of each serum sample 
was added to the other tubes each containing 775 µL of distilled water to bring the total 
volume to 800 ml.  All tubes had the addition of the following in sequence, using auto 
repeat pipettes: 200 µL of SDS; 1.5 ml of TBA; and 1.5 ml of glacial acetic acid 
solutions, succeeded by mixing with a vortexer.  The test tubes were then placed in a 
95°C glycol bath for one hour after which they were allowed to cool for ten minutes.  
Then, 1 ml of DD water was added to each, followed by the addition of 5 ml of pyridine: 
butanol solution in order to extract the thiobarbituric acid reactive substances. 
Subsequently, the tubes were capped and vortexed for 60 seconds followed by 
centrifugation at 3000 RPM for 15 minutes.  Lastly, the supernant was individually 
 58
pipetted and placed in a fluorescence spectrophotometer and read at an excitation of 515 
nm and an emission of 553 nm. 
2.2.3.1 Calculation of MDA 
The concentration of MDA in serum can be calculated as follows: 
     0.25 nmol                            f 
_______________         X      __________________          X        Dilution factor                                             (4.0)              
           F                        Vol. of Sample 
 
Where: F= Standard   -   Blank                                            (4.1) 
             f= Sample – Blank                                                  (4.2) 
* Serum MDA concentration is reported in nmol / ml (µmol/L) 
2.2.4 Plasma Preparation for Homocysteine Assay 
 Arterial blood was drawn and transferred into tripotassium EDTA vacutainer 
tubes (EM Sciences, Merck KgaA, Germany).  Samples were refrigerated at 4°C for up 
to six hours prior to centrifugation at 3000 RPM for 10 minutes to separate the plasma 
from the cellular constituents of the blood.  Plasma was then pipetted into labeled 
Eppendorf Tubes and stored at -80°C until assayed.  Samples were mixed thoroughly 
after thawing to ensure consistency. 
2.2.5 Materials for Homocysteine Assay 
 The homocysteine reagent pack (Abbot Laboratories, USA) was refrigerated at 
4°C until utilized for assay.  The kit was composed of sample cartridges, cuvettes, and 
four bottles of the following solutions: (1) 4.5 ml pretreatment solution (containing 
dithiothreitol {DTT} and adenosine in citric acid); (2) 10.5 ml S-adenosyl-L-
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homocysteine Hydrolase solution; (3) 10.5 ml Anti-S-adenosyl-L-homocysteine 
Antibody (mouse monoclonal); and (4) 10.5 ml S-adenosyl-L-cysteine Fluorescein 
Tracer. 
 The calibrators for the homocysteine assay were stored at 2-8°C and consisted of   
five different types: calibrator A, 3.5 ml phosphate buffer solution, and calibrators B-F 
consisting of 2.5 ml of varying concentrations of S-adenosyl-L-homocysteine (SAH).  
The concentrations of S-adenosyl-L-homocysteine in bottles A-F were 0.0, 2.5, 5.0, 
10.0, 20.0, and 50.0 µmol/L respectively.  The calibrators functioned to check the 
accuracy of the instrument by measurement of its variation from the standard.  The 
instrument was calibrated with each new homocysteine reagent pack.   
 The three controls (Low, Medium and High) have a volume of 2.5 ml, each 
consisting of IMx homocysteine.  The low, medium and high controls had 
concentrations of 7 µmol/L with a range of 5.25 - 8.75 µmol/L; 12.5 µmol/L with a 
range of 10.0 - 15.0 µmol/L; and 25.0 µmol/L with a range of 20.0 - 30.0 µmol/L 
respectively.  Essentially, they are used as standards against which the sample results 
may be evaluated. All three controls were incorporated into each run of plasma samples. 
2.2.6 Method for Homocysteine Assay 
 An Abbot IMx instrument utilizing fluorescence polarization (FPIA) technology 
was used to measure total homocysteine in the plasma samples.  A 50 µL aliquot of 
plasma is the minimum volume required to perform the assay.  The biological properties 
of the procedure involve the reduction of homocysteine, mixed disulphide, and protein 
bound forms of homocysteine in the sample to form free homocysteine under the 
influence of the enzyme dithiothreitol.  Next, the total free homocysteine is transformed 
to S-adenosyl-L-homocysteine (SAH) by the enzyme SAH Hydrolase and residual 
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adenosine.  Successively, the unified chemical form of homocysteine (SAH) and the 
labeled Fluorescein Tracer (both of which are antigens) contend for sites on the 
monoclonal antibody molecule.  The polarization from the fluorescein-antigen conjugate 
is determined by its rate of rotation during the lifetime of the excited state in solution.  
Thus, the binding of the antigen to the antibody (Anti-S-adenosyl-L-homocysteine 
Antibody) changes the polarization. Finally, the intensity of the polarization is measured 
by the FPIA optical assembly and related to the known antigen concentration 
(Shipchandler et al. 1995). 
2.3 STATISTICAL ANALYSIS 
 Statistical analysis was performed utilizing the Statistical Program for the Social 
Sciences version 13.0 (SPSS).  The results were expressed as mean ± standard error 
mean (SEM). In addition, an unpaired “T” test was used to compare data between 
groups.  Finally, a value of p< 0.05 was considered significant. 
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3.0 RESULTS 
3.1 DEMOGRAPHIC CHARACTERISTICS OF PATIENTS 
 Demographic and clinical features of patients who developed restenosis and 
those who did not following PCI are shown in Table I.  Seventy-seven percent of the 
patients who underwent PCI and developed restenosis had a positive ETT at 2 weeks 
post-PCI.  However, 23% of the patients who underwent PCI and developed restenosis 
had a negative ETT at 2 weeks post-PCI.   Fourteen percent of the patients who did not 
developed post PCI restenosis had a positive 2 week ETT.  Whereas, 86% of the patients 
who did not develop post PCI restenosis had a negative ETT at 2 weeks.  All of the 
patients that developed post-PCI restenosis had a positive ETT at 6-months.  None of the 
patients that developed post-PCI restenosis had a negative ETT at 6-months.  Seven 
percent of the patients who did not develop post-PCI restenosis had a positive ETT at 6-
months.  However 93% of the patients who did not develop post-PCI restenosis had a 
negative ETT at 6-months.  The number of diseased vessels and number of coronary 
lesions were similar in the two groups and are summarized in Table 2.  The results of the 
lipid profile were divided into those patients who developed restenosis following PCI 
(Group I) and those who did not (Group II).  Eighty-six percent of the patients in Group 
I and 55% of the patients Group II were hypercholesterolemic (above 6.2 mmol/L for 
patients above 65 years of age) respectively.  In addition, 14% of the patients from 
Group I and 45% of the patients from Group II had total cholesterol levels within the 
normal range (4.2-6.2 mmol/L).  Fifty-five percent of the patients that developed post-
PCI restenosis had a history of hypertension (>150/90 mmHg) while 45% did not.  
Moreover, 52% of the patients that did not develop post-PCI restenosis had a history of 
hypertension while 48% did not.  In patients that developed post-PCI restenosis 32% 
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were smokers while 50% were ex-smokers.  In patients who did not develop post-PCI 
restenosis 17% were smokers and 34% were ex-smokers.  Age and sex were similar in 
both groups, the patients being mainly males. The age of patients who developed post-
PCI restenosis (n=22) ranged from 43 to 76 (mean 60.5 ± 2.0) years.  The age of patients 
who did not develop post-PCI restenosis (n=29) also ranged from 43 to 76 (mean 59.9 ± 
2.0) years.  There was no significant difference in age between the two groups (p=0.85).  
There were 51 patients enrolled in the study.  There were 45 males and 6 females.  
Forty-four percent of the males developed post-PCI restenosis while 56% of the males 
did not.  Thirty-three percent of the females developed post-PCI restenosis while 67% 
did not.  From the demographic data it appears that a significant number of patients who 
developed restenosis were hypercholesterolemic.  In addition, there were more 
nonsmokers in the group that did not develop post-PCI restenosis. 
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TABLE 1: Demographic and clinical characteristics for patients with and without 
post-PCI coronary restenosis. 
NO. Characteristic Restenosis Non-restenosis 
1 Hypercholesterolemia 86% 55% 
2 Normal Cholesterol Range 14% 45% 
3 History of Hypertension 55% 52% 
4 Normotensive 45% 48% 
5 Smoker 32% 17% 
6 Ex-smoker 50% 34% 
7 2 week positive ETT 77% 14% 
8 6 month positive ETT 100% 7% 
9 2 week negative ETT 23% 86% 
10 6 month negative ETT 0% 93% 
11  Age in years (mean ± SE) 60.5 ± 2.0 59.5 ± 2.0 
12 # of Males 20 25 
13 # of Females 2 4 
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Table 2: Diseased Vessel and Number of Lesions in Patients with and without post-
PCI Restenosis 
 
            Patients with Restenosis                                   Patients without Restenosis                     
 
Patient 
Number 
 
Diseased 
Vessel 
Number of 
Lesions 
Patient 
Number 
Diseased 
Vessel 
Number of 
Lesions 
1 LAD Single 1 CX Single 
2 CX Double 2 RCA Triple 
3 RCA Single 3 LAD/DIAG Double 
4 RCA/CX Double 4 LAD Double 
5 LAD Triple 5 RAMUS/RCA Double 
6 LAD Triple 6 CX Triple 
7 RCA Single 7 RCA Single 
8 LAD/DIAG Triple 8 LAD Single 
9 RCA Single 9 LAD Triple 
10 RCA Single 10 CX Single 
11 RCA Triple 11 RCA Double 
12 RCA/CX Double 12 LAD Double 
13 LAD/CX Triple 13 DIAG Single 
14 LAD Single 14 RCA Double 
15 CX Single 15 RCA Double 
16 CX Double 16 LAD Double 
17 RCA Single 17 LAD Double 
18 RCA Triple 18 LAD Double 
19 LAD Single 19 RCA Single 
20 LAD Single 20 RCA Single 
21 OM Single 21 LAD/DIAG Double 
22 DIAG Double 22 LAD Single 
   23 CX Single 
   24 LAD Single 
   25 OM Double 
   26 LAD Double 
   27 RCA Double 
   28 Ramus/RCA Single 
   29 LAD/CX Double 
 
 
LAD, left anterior descending; CX, circumflex; RCA, right coronary artery; Diag, 
diagonal; OM, obtuse marginal; Ramus, Ramus Intermedius  
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 3.2 SERUM MALONDIALDEHYDE 
 The changes in serum malondialdehyde for the five observed time intervals are 
summarized in Figure 1.  The pre-procedural serum MDA levels in patients with (Group 
I) and without (Group II) restenosis were 0.124 ± 0.016 and 0.147 ± 0.016 nmol/mL 
respectively.  There was no significant difference (p= 0.60) between these two groups. 
At the 0 time interval the values of serum MDA of those patients who developed 
restenosis and those patients who did not were 0.082 ± 0.009 and 0.135 ± 0.014 
nmol/mL respectively.  There was a significant difference (p=0.001) in the values of 
serum MDA between the two groups. In addition, the values of serum MDA decreased 
significantly (p=0.03) at the 0 time interval from the pre-procedural levels in the 
restenosis group.  In the non-restenosis group there was no significant difference 
(p=0.73) between the preprocedural levels and the values from the 0 time interval.   
 At the 8 hr time interval the values of serum MDA of those patients who 
developed post-PCI restenosis and those who did not were 0.165 ± 0.42 and 0.158 ± 
0.02 nmol/mL respectively.  There was no significant difference (p= 0.88) between the 
two groups.  There was also no significant difference between the 8 hr values of serum 
MDA as compared to the pre-procedural values of those patients who developed 
(p=0.36) or those patients who did not develop (p=0.67) post-PCI restenosis.    
At the 24 hr time interval the values of serum MDA for those patients who 
developed post-PCI restenosis and those who did not were 0.12 ± 0.001 and 0.140 ± 
0.017 nmol/mL respectively. There was a significant difference (p=0.033) between the 
two groups. In addition, there was no significant difference between the pre-procedural 
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values as compared to the 24 hr values in those patients who developed (p=0.17) 
restenosis and those who did not (p=0.78).  
 At the 6-month time interval the values of serum MDA for those patients who 
developed restenosis and those who did not were 0.224 ± 0.016 and 0.198 ± 0.017 
nmol/mL respectively.  There was no significant difference (p=0.28) between the two 
groups. There was also no significant difference (p=0.053) between the pre-procedural 
values and the 6-month post-PCI values in those patients who did not develop restenosis.  
However, there was a significant difference (p=0.001) between the pre-procedural 
values as compared to the 6-month post-PCI values in those patients who developed 
restenosis.  
The percentage of pre-procedural percutaneous coronary interventional serum 
MDA values for the five observed time intervals are summarized in Figures 2 and 3.  
There was a significant increase of 109% (p=0.001) in the 6-month post-PCI values as 
compared to the pre-procedural levels in the restenosis groups.  However, there was not 
a significant increase (41%, p=0.09) in the 6-month post-PCI values as compared to the 
pre-procedural levels in the non-restenosis group.  
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Figure 1 The levels of malondialdehyde (MDA) before percutaneous coronary 
intervention (pre-PCI), and at 0 hrs, 8 hrs, 24 hrs and 6-months post-PCI in patients with 
and without restenosis.  Results are expressed as mean ± SE.  *P<0.05, pre-PCI vs. 0 hrs 
or 6 months in the restenosis group. 
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Figure 2 The percentage of pre-procedural percutaneous coronary interventional (pre-
PCI) malondialdehyde (MDA) values at 0 hrs, 8 hrs, 24 hrs and 6-months post-PCI in 
patients with restenosis.  Results are expressed as mean ± SE.  *P<0.05, pre-PCI vs. 0 
hrs or 6 months. 
 
 69
  
 
 
 
Figure 3 The percentage of pre-procedural percutaneous coronary interventional (pre-
PCI) malondialdehyde (MDA) values at 0 hrs, 8 hrs, 24 hrs and 6-months of post-PCI in 
patients without restenosis.  Results are expressed as mean ± SE. 
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3.3 PLASMA HOMOCYSTEINE 
The changes in the plasma homocysteine levels for the four observed time 
intervals are summarized in Figure 4.  The pre-procedural plasma homocysteine levels in 
patients with and without post-PCI restenosis were 10.37 ± 0.46 and 10.73 ± 0.49 
µmol/L respectively.  There was no significant difference (p=0.60) between the two 
groups.  
At the 8 hr time interval the values of plasma homocysteine of those patients 
who developed restenosis and those who did not were 10.40 ± 0.43 and 10.16 ± 0.47 
µmol/L respectively.  There was no significant difference in the values (p=0.71) between 
the two groups.  There was also no significant difference between the pre-procedural 
values of plasma homocysteine as compared to the 8 hr values of the restenosis (p=0.95) 
or the non-restenosis group (p=0.40). 
At the 24 hr time interval the values of plasma homocysteine of those patients 
who developed restenosis and those who did not were 9.01 ± 0.42 and 8.92 ± 0.43 
µmol/L respectively.  There was no significant difference (p= 0.88) between the two 
groups.  However, there was a significant decrease in the values of plasma homocysteine 
in both the restenosis (p=0.04) and non-restenosis (p= 0.01) groups at 24 hrs as 
compared to the pre-procedural levels.  
At the 6-month time interval the values of plasma homocysteine of those patients 
who developed post-PCI restenosis and those who did not were 12.45 ± 0.43 and 11.40 
± 0.80 µmol/L respectively. There was no significant difference (p=0.96) in the values 
between the two groups. The pre-procedural levels of plasma homocysteine were not 
significantly different (p=0.82) as compared to the 6-month post-PCI values of 
homocysteine in the non-restenosis group.  However, the pre-procedural values of 
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plasma homocysteine were significantly different (p=0.002) as compared to the 6-month 
post-PCI values of plasma homocysteine in those patients who developed restenosis.  
The percentage of pre-procedural percutaneous coronary interventional plasma 
homocysteine values for the four observed time intervals are summarized in Figures 5 
and 6.  In patients who developed restenosis, there was a significant (p=0.001) increase 
in the values of plasma homocysteine from the pre-procedural levels of 24% at the 6-
month time interval. In patients who did not develop restenosis there was an increase of 
16% in the values of plasma homocysteine at the 6-month interval as compared to the 
pre-procedural levels, however this increase was not significant (p=0.80).  
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Figure 4 The levels of plasma homocysteine before percutaneous coronary intervention 
(pre-PCI), and at 8 hrs, 24 hrs and 6-months post-PCI in patients with and without 
restenosis.  Results are expressed as mean ± SE.  *P<0.05, pre-PCI vs. 24 hrs or 6 
months in the restenosis group. *P<0.05, pre-PCI vs. 24 hrs in the non-restenosis group. 
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Figure 5 The percentage of pre-procedural percutaneous coronary interventional (pre-
PCI) homocysteine values at 8 hrs, 24 hrs and 6-months post-PCI in patients with 
restenosis.  Results are expressed as mean ± SE.  *P<0.05, pre-PCI vs. 24 hrs or 6 
months. 
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Figure 6 The percentage of pre-procedural percutaneous coronary interventional (pre-
PCI) homocysteine values at 8 hrs, 24 hrs and 6-months post-PCI in patients without 
restenosis.  Results are expressed as mean ± SE.  *P<0.05, pre-PCI vs. 24 hrs. 
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 3.4 CHOLESTEROL 
 A lipid profile (total cholesterol, triglycerides, HDL-C and LDL-C) was 
determined on all patients entering the study.  The results of the lipid profile were 
divided into those patients who developed restenosis following PCI (Group I) and those 
who did not (Group II).   
3.4.1 Serum Total Cholesterol 
  The values of total cholesterol are summarized in Figure 7.  The patients in 
Group I had a serum total cholesterol range from 2.85 to 8.24 (mean 5.05 ± 0.31) 
mmol/L while those patients in Group II had a serum total cholesterol range from 2.25 to 
5.24 (mean 3.88 ± 0.12) mmol/L.   The values were significantly (p=0.001) higher in 
Group I as compared to Group II. 
3.4.2 Serum Triglycerides 
 The values of serum triglyceride are summarized in Figure 8.  The serum 
triglyceride levels of those patients in Group I ranged from 1.29 to 4.18 (mean 2.40 ± 
0.18) mmol/L while those patients in Group II had a serum triglyceride range from 0.61 
to 3.91 (mean 1.89 ± 0.17) mmol/L.  The values of the two groups were not significantly 
different from each other (p=0.058). 
3.4.3 Serum HDL-C  
The values of serum HDL-C are summarized in Figure 9.  The serum HDL-C 
levels of those patients in Group I ranged from 0.30 to 1.48 (mean 0.86 ± 0.07) mmol/L 
while those patients in Group II ranged from 0.65 to 1.86 (mean 1.18 ± 0.06) mmol/L.  
The values were significantly (p=0.001) lower in Group I as compared to Group II. 
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3.4.4 Serum LDL-C   
The values of serum LDL-C are summarized in Figure 10.  The serum LDL-C 
levels of those patients in group I ranged from 1.3 to 5.47 (mean 2.90 ± 0.23) mmol/L 
while the levels of those patients in group II ranged from 0.43 to 4.91 (mean 2.17 ± 
0.20) mmol/L.  The values were significantly (p=0.02) higher in Group I as compared to 
Group II. 
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Figure 7 The pre-procedural percutaneous coronary interventional (pre-PCI) levels of 
serum total cholesterol in patients with and without post-PCI restenosis. Results are 
expressed as mean ± SE.  *P<0.05, restenosis vs. non-restenosis. 
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Figure 8 The pre-procedural percutaneous coronary interventional (pre-PCI) levels 
serum triglyceride in patients with and without post-PCI restenosis. Results are 
expressed as mean ± SE.   
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Figure 9 The pre-procedural percutaneous coronary interventional (pre-PCI) levels of 
serum HDL-C in patients with and without post-PCI restenosis. Results are expressed as 
mean ± SE.  *P<0.05, restenosis vs. non-restenosis. 
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Figure 10 The pre-procedural percutaneous coronary interventional (pre-PCI) levels of 
serum LDL-C in patients with and without post-PCI restenosis. Results are expressed as 
mean ± SE.  *P<0.05, restenosis vs. non-restenosis. 
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3.6 HOMOCYSTEINE, SMOKING AND RESTENOSIS 
 The values of plasma homocysteine in smokers and non-smokers are 
summarized in Figures 11 and 12.  The plasma homocysteine levels were analyzed for 
patients who developed restenosis and were divided into smokers and non-smokers.  The 
pre-procedural plasma homocysteine concentrations for those patients who developed 
post-PCI restenosis and smoked and those who developed post-PCI restenosis and were 
non-smokers were 9.60 ± 0.51 and 10.72 ± 1.3µmol/L respectively.  The values were not 
significantly different (p=0.46) between the groups.   
At the 8 hr time interval the levels of plasma homocysteine of smokers and non-
smokers who developed post-PCI restenosis were 10.34 ± 0.60 and 11.21 ± 1.6 µmol/L 
respectively.  The values were not significantly different (p=0.63) between the groups.  
There was also no significant difference between the pre-procedural values of plasma 
homocysteine as compared to the 8 hr values of smokers (p=0.37) or non-smokers 
(p=0.82) who developed restenosis. 
At the 24 hr time interval the levels of plasma homocysteine of smokers and non-
smokers who developed post-PCI restenosis were 8.91 ± 0.35 and 8.32 ± 1.20 µmol/L 
respectively.  The values were not significantly different (p=0.65) between the groups.  
There was also no significant difference between the pre-procedural values of plasma 
homocysteine as compared to the 24 hr values of smokers (p=0.29) or non-smokers 
(p=0.21) who developed restenosis. 
 At the 6-month time interval the values of plasma homocysteine for smoking 
and non-smoking patients who developed post-PCI restenosis were 11.45 ± 0.56 and 
13.89 ± 1.8 µmol/L respectively.  The values were not significantly different (p=0.26) 
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between the groups.  There was also no significant difference (p=0.21) between the pre-
procedural levels of plasma homocysteine as compared to the 6-month values in non-
smokers who developed restenosis.  However, there was a significant difference 
(p=0.03) between the pre-procedural levels of plasma homocysteine as compared to the 
6-month concentrations in smokers who developed restenosis. 
3.7 MDA, SMOKING AND RESTENOSIS 
 The values of serum MDA for cigarette smokers and non-smokers are 
summarized in Figures 13 and 14.  The serum MDA levels were analyzed for smokers 
and non-smokers who developed post-PCI restenosis.  The pre-procedural serum MDA 
concentrations for smokers and non-smokers who developed post-PCI restenosis were 
0.127 ± 0.031 and 0.120 ± 0.04 nmol/mL respectively.   The values were not 
significantly different (p=0.83) between the groups.   
At 0 time interval the levels of serum MDA for smoking and non-smoking 
patients who developed post-PCI restenosis were 0.08 ± 0.02 and 0.11 ± 0.04 nmol/mL 
respectively. The values were not significantly different (p=0.47) between the groups.   
There was also no significant difference between the pre-procedural values of serum 
MDA as compared to the 0 time interval values in the smoking (p=0.18) or non-smoking 
(p=0.86) groups. 
At the 8 hr time interval the levels of serum MDA for smoking and non-smoking 
patients who developed post-PCI restenosis were 0.11 ± 0.03 and 0.252 ± 0.22 nmol/mL 
respectively.  The values were not significantly different (p=0.35) between the groups.  
There was also no significant difference between the pre-procedural values of serum 
MDA as compared to the 8 hr time interval values in the smoking (p=0.71) or non-
smoking (p=0.36) groups. 
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At the 24 hr time interval the levels of serum MDA for smoking and non-
smoking patients who develop post-PCI restenosis were 0.10 ± 0.02 and 0.12  ± 0.04 
nmol/mL respectively.  The values were not significantly different (p=0.92) between the 
groups.  There was also no significant difference between the pre-procedural values of 
serum MDA as compared to the 24hr time interval values in the smoking (p=0.39) or the 
non-smoking (p=0.10) groups. 
At the 6-month time interval the levels of serum MDA for smoking and non-
smoking patients who develop post-PCI restenosis were 0.19 ± 0.03 and 0.24 ± 0.04 
nmol/mL respectively.  The values were not significantly different (p=0.37) between the 
groups.  There was also no significant difference between the pre-procedural values of 
serum MDA as compared to the 6-month time interval values in the smoking (p=0.14) or 
the non-smoking (p=0.07) groups. 
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Figure 11 The levels of plasma homocysteine before percutaneous coronary 
intervention (pre-PCI), and at 8 hrs, 24 hrs and 6-months post-PCI in smokers who 
developed restenosis.  Results are expressed as mean ± SE.  *P<0.05, pre-PCI vs. 6 
months in the restenosis group. 
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Figure 12 The levels of plasma homocysteine before percutaneous coronary 
intervention (pre-PCI), and at 8 hrs, 24 hrs and 6-months post-PCI in non-smokers who 
developed restenosis.  Results are expressed as mean ± SE.    
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Figure 13 The levels of serum malondialdehyde (MDA) before percutaneous coronary 
intervention (pre-PCI), and at 0 hrs, 8 hrs, 24 hrs and 6-months post-PCI in smokers who 
developed restenosis.  Results are expressed as mean ± SE.    
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Figure 14 The levels of serum malondialdehyde (MDA) before percutaneous coronary 
intervention (pre-PCI), and at 0 hrs, 8 hrs, 24 hrs and 6-months post-PCI in non-smokers 
who developed restenosis.  Results are expressed as mean ± SE.    
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4.0 DISCUSSION 
 The results of the present study suggest that the pre-procedural level of plasma 
homocysteine is not a predictor of restenosis.  However, the post-PCI levels of 
homocysteine are associated with restenosis.  Earlier reports on the pre-procedural 
plasma level of homocysteine as a predictor of restenosis are controversial.  Total 
plasma homocysteine has been suggested as a factor of post-PCI restenosis (Schnyder et 
al. 2001; Kumbasar et al. 2001; Morita et al. 2000).  In addition, Schnyder et al. (2002b) 
demonstrated that lowering plasma homocysteine levels attenuates post-PCI restenosis.  
SoRelle (2001) reported that folic acid consumption reduces plasma homocysteine levels 
and decreases post-PCI restenosis.  On the contrary, there are reports which suggest that 
elevated levels of plasma homocysteine were not predictors of post-PCI restenosis 
(Hodish et al. 2002; Miner et al. 2000).  In addition, Genser et al. (2002) reported that 
there is no correlation between plasma levels of homocysteine and in-stent coronary 
restenosis.  Nevertheless, it has been demonstrated that homocysteine is toxic to 
endothelial cells (Blundell et al. 1996; Wall et al. 1980; Jones et al. 1994).  This 
controversy could be due to dominant factors other than homocysteine (i.e. OR 
generation) that could damage endothelial cells and initiate the development of 
atherosclerosis and restenosis. It is plausible that the presence of elevated levels of 
plasma homocysteine may exist with low levels of OR’s (measured indirectly by MDA 
levels) and increased levels of antioxidants in the tissue.  Under these circumstances the 
coronary artery may not undergo post-PCI restenosis.  However, it is also plausible that 
hyperhomocysteinemia could induce endothelial cell damage through oxygen free 
radical production (auto-oxidation of homocysteine) and possibly set the stage for 
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restenosis (Blundell et al. 1996; Jones et al. 1994; Wall et al. 1980; Harker et al. 1974; 
Starkebaum and Harlan 1986; Weimann et al. 1980; Anderson et al. 1995). 
4.1 HOMOCYSTEINE AND RESTENOSIS 
 Restenosis following successful PCI continues to be an adverse outcome of this 
procedure.  All patients of the present study (n=51) were implanted with bare metal 
stents. Our post-PCI restenosis rate was 43% which is consistent with the reported 
restenosis rates in the literature (Erbel et al. 1996).  The numerous data that correlate 
homocysteine with the risk of the development, and the severity of CAD has stimulated 
interest in its possible function in restenosis (Prasad, 1999; Christen et al. 2000; 
Schnyder et al. 2002a).  Homocysteine-induced smooth muscle cell proliferation, loss of 
endothelial function, coagulation abnormalities and plasma lipoprotein oxidation (from 
OR generation) associated with atherogenesis may contribute to restenosis as well.  Thus 
the investigation of the governed release of intracellular homocysteine release into the 
plasma may provide a feasible biochemical marker for restenosis (Schnyder et al. 
2001b).  This study has demonstrated that patients who developed restenosis had a 
significant increase in the values of plasma homocysteine from the pre-procedural levels 
as compared to the 6-month post-PCI values. This suggests that the post-PCI values are 
predictors of restenosis. Perhaps this would explain why SoRelle (2001) found that 
lowering plasma homocysteine levels with folic acid consumption decreased post-PCI 
restenosis.  In addition, Schnyder et al. (2002) demonstrated that lowering plasma 
homocysteine levels attenuates post-PCI restenosis; however the levels of homocysteine 
were only measured pre-procedurally and at 6-months follow-up. 
 In the present study, the significant increase in the plasma levels of post- PCI 
homocysteine as compared to pre-procedural levels in patients who developed restenosis 
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could be attributed to the greater number of patients in the restenosis group (55%) who 
had a history of cigarette smoking.  The patients who developed restenosis post-PCI 
demonstrated a significant difference (p=0.031) between the pre-procedural values of 
plasma homocysteine in the smokers group (9.60 ± 0.51 μmol/L) as compared to the 6-
month post-PCI plasma homocysteine levels of the same group (11.45 ± 0.056 μmol/L). 
This observation is supported by the study conducted by Nygard et al. (1995) in which 
they showed that cigarette smoking increases plasma homocysteine levels.  Nygard et al. 
(1995) compared current smokers to non-smokers and found that current smokers had a 
higher plasma homocysteine level that rose linearly with the number of cigarettes 
smoked/day.  Specifically, cigarette smokers with a plasma homocysteine level above 12 
mmol/L had a 12 times the risk of developing cardiovascular disease compared to non-
smokers with homocysteine levels with the normal range (O’Callaghan et al. 2002; El-
Khairy et al. 1999). The risk of developing cardiovascular disease among ex-smokers 
was similar to that of current smokers (O’Callaghan et al. 2002; El-Khairy et al. 1999).   
Incidentally, in the present study, over half of the patients who developed restenosis 
post-PCI were ex-smokers.  However, information pertaining to when the patients quit 
smoking is not available.  Nevertheless, vitamins B6, B12, and folate were higher in non-
smokers than in those who smoked (O’Callaghan et al. 2002; El-Khairy et al. 1999).   
The explanation for the increased plasma homocysteine levels among patients with a 
history of smoking is not clear.  However, smoking is associated with differing plasma 
thiol redox status, perhaps due to the formation of ORs (Mansoor et al. 1995).  
According to Kalra et al. (1991) the serum concentration of ORs is increased in cigarette 
smokers.  Cigarette smoking has been associated with increased risk of the development 
of atherosclerosis (Friedman et al. 1979). However, the present study was unable to 
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establish a positive correlation between MDA, restenosis, and smoking.   The lack in 
correlation of the results from the present study in comparison to the Kalra et al. (1991 
could be due to the small sample size. The results of the present study revealed that the 
patients who developed restenosis post-PCI showed no significant difference (p=0.137) 
between the pre-procedural values of serum MDA in the smokers group compared to the 
6-month post-PCI serum MDA levels of the same group.  There was also no significant 
difference between the pre-procedural levels of MDA and the 6-month post-PCI levels 
of MDA in the restenosis nonsmoker group. 
As outlined by Prasad (1999), during smoking polymorphonuclear leukocytes are 
stimulated by nicotine-induced C5a generation which in turn may lead to the production 
of peroxyl radicals (by-products of cigarette smoke) that could injure endothelial cells 
(Kalra et al. 1991).  ORs can induce endothelial injury and can propagate and maintain 
atherogenesis and restenosis.   In addition, the ORs produced from smoking may induce 
atherosclerosis by stimulating clotting factors and cause smooth muscle cell 
proliferation.  Smooth muscle cell hyperplasia (proliferation) is central to the 
development of post-PCI restenosis. 
4.2 OXIDATIVE STRESS AND RESTENOSIS 
Eighty-six percent of the patients in this study who developed restenosis had a 
history of hypercholesterolemia.  Hypercholesterolemia may increase serum 
concentrations of ORs through multiple mechanisms.  Hypercholesterolemia has been 
demonstrated to amplify the cholesterol content of PMNLs, platelets and endothelial 
cells (Gorg and Kakkar, 1987; Prisco et al. 1986; Stuart et al. 1980; Prasad, 2001).  
Platelets that are high in cholesterol liberate adenosine diphosphate (ADP), thrombin, 
and histamine (Henry, 1977; Shattil et al. 1975).  Histamine and ADP stimulate 
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phospholipase A2 that acts on membrane phospholipids causing the release arachidonic 
acid (Ruzicka and Printz, 1984; Vanden, 1980).  Hypercholesterolemia is associated 
with increased intracellular Ca2+ concentrations which can also increase phospholipase 
A2 (Quan-sang et al. 1987; Vanden, 1980).  The arachidonic acid stimulates an increase 
in the synthesis of leukotrienes and prostaglandins through the lipoxygenase and 
cyclooxygenase pathways respectively.  ORs are produced during biosynthesis of 
leukotrienes and prostaglandins from arachidonic acid (Egan et al. 1976; Marnett et al. 
1975; Murota et al. 1990; Panganamala et al. 1976).  Hypercholesterolemia may also 
indirectly produce ORs and hypochlorous acid (HOCl) from leukocytes that are 
activated by platelet activating factor (PAF), leukotriene B4, (LTB4) and activated 
complement components (C3a and C5a) (Ford-Hutchinson et al. 1980; Hanahan, 1986; 
Fantone and Ward, 1982; Prasad et al. 1989; Vanden, 1980; Whatley et al. 1989; 
Steward et al. 1990).  LTB4 could be produced by the aforementioned mechanism of 
arachidonic acid metabolism, while PAF formation and release is dependent on 
intracellular Ca2+ concentrations and plasma thrombin which are elevated during 
hypercholesterolemia.  Oxygen radicals (superoxide anion, hydroxyl radical, hydrogen 
peroxide and HOCl) are associated with tissue injury and atherogenesis (Gupta and 
Prasad, 1992a; Jolly et al. 1984; McCord, 1985).  ORs exert their effect on unsaturated 
fatty acids of the lipid membrane to generate lipid peroxides (MDA) which in turn 
increases membrane permeability with a loss of membrane integrity (Freeman and 
Crapo, 1982). An increase in serum MDA suggests the participation of ORs in tissue 
damage.   In the present study there was a significant increase (p=0.001) in serum MDA 
from the pre-procedural values as compared to the 6-month post-PCI values in the 
patients who developed restenosis.  Therefore, it is possible that hypercholesterolemia 
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may increase the levels of ORs and may be responsible for endothelial injury (Prasad et 
al. 1994) possibly mediating initiation of restenosis.  Endothelial injury constitutes a 
crucial step in initiating the development in the pathogenesis of atherosclerosis and 
perhaps coronary restenosis (Ross, 1986; Thambyrajah and Townsend, 2000).  Prasad et 
al. (1994) demonstrated that hypercholesterolemic atherosclerosis is correlated with an 
increase in aortic tissue MDA and decreased antioxidant reserve.  These results also 
suggest that increased aortic tissue MDA is related to an increased level of OR 
production and or decreased antioxidant reserve.  Prasad et al. (1994) have shown that 
ORs are involved in the development and maintenance of hypercholesterolemic 
atherosclerosis.  Cholesterol-lowering agents combined with niacin therapy have been 
reported to increase plasma homocysteine levels (Blankenhorn, 1991).  Sixty-eight 
percent of the patients in the present study were on cholesterol lowering agents with 
niacin therapy which may explain the post-PCI six-month increase in plasma 
homocysteine levels as compared to baseline in those patients who developed restenosis.  
On the other hand, two studies which investigated the administration of lipid lowering 
agents’ post-PCI and their ability to reduce restenosis found that there was no uniform 
significant difference in angiographic or clinical restenosis as compared to those patients 
who received placebo (Serruys et al. 1999; Serruys et al. 2002).  However, their role in 
limiting the development and progression of atherosclerosis is of importance (Kinlay et 
al. 1996).  For instance, many primary and secondary prevention trials using 3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitors (statins) have shown reductions in 
mortality and morbidity in patients with CAD (Maron et al. 2000; Schwartz et al. 2001).  
The results of the present study show that the serum levels of total cholesterol (p=0.001) 
and LDL-C (p=0.02) were significantly higher and serum HDL-C levels (p=0.001) were 
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significantly lower in patients who developed post-PCI restenosis than in patients who 
did not develop post-PCI restenosis.  These results suggest that there is an association 
between hypercholesterolemia and post-PCI restenosis.  It is possible that the ORs 
generated from hypercholesterolemia play a role in the genesis of post-PCI restenosis. 
 Rodrigo et al. (2003) reported that there was an association between essential 
hypertension and elevated levels of plasma homocysteine.  The results of the present 
study show that 55% percent of the patients who developed restenosis had a history of 
hypertension.  As described by Prasad et al. (1991) homocysteine impairs vascular 
smooth muscle and endothelial cell function by altering endothelial dependent 
vasomotor regulation.  The mechanism by which elevated concentrations of plasma 
homocysteine contributes to hypertension may be multi-factorial.  Homocysteine 
decreases vasodilation by the inhibition of nitric oxide.  It increases oxidative stress by 
the generation of ORs, thereby inducing vascular smooth muscle cell proliferation and 
alterations of the elastic qualities of the vascular wall leading to hypertension-induced 
atherosclerosis and possibly restenosis.  According to Stamler and Slivka (1996), 
endothelial relaxations are dependent on the bioavailability of endothelial NO synthetase 
(eNOS) to produce nitric oxide.  Nitric oxide is critical for sustaining vascular 
homeostasis (Rodrigo et al. 2003).  The effect of preservation of the endothelium by NO 
is weakened by hyperhomocysteinemia (Prasad, 1999). Thus, vascular injury is due to a 
disproportional between NO production and the concentrations of homocysteine.  In 
addition, the lipid peroxidation produced by elevated levels of homocysteine may 
attenuate the expression of eNOS and catabolize NO (Blom et al. 1995; Chin et al. 1992; 
Liao et al. 1995).  Homocysteine is also involved in essential hypertension through its 
production of ORs.  Oxygen radicals may cause the release of Ca2+ from the 
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sarcoplasmic reticulum and mitochondria resulting in increased vascular tone (Tsai et al. 
1994).  Lastly, it has been suggested by Tsai et al. (1994) that homocysteine may play a 
role in the development of smooth muscle cell proliferation.  Moreover, elevated plasma 
homocysteine concentrations have been observed in patients with carotid artery intimal 
thickening suggesting an increase in vascular tone (Willinek et al. 1997). Thus, the 
relationship between homocysteine–induced hypertension and atherosclerosis is strong 
and it is possible that there may be an association between homocysteine-induced 
hypertension and post-PCI restenosis. 
 Studies have demonstrated a correlation between restenosis and the fibrinolytic 
system.  Huber et al. (1992) found an increase in the procoagulant protein plasminogen 
activator inhibitor-1 (PAI-1) concentrations post-PCI in patients with restenosis and a 
decrease in PAI-1 from baseline in those patients who did not develop restenosis.  Lang 
et al. (2000) showed that exposure of cultured endothelial cells to homocysteine led to 
an increase in the intracellular production of superoxide anion. It has also been 
demonstrated that superoxide anion and singlet oxygen produce thrombus formation 
(Jourdan et al. 1995).  It is possible that the oxidative stress produced by the auto-
oxidation of homocysteine is related to thrombus-induced restenosis post-PCI.  
Superoxide anion, hydroxyl radicals and hydrogen peroxide are produced during the 
auto-oxidation of homocysteine (Welch et al. 1996; Misra, 1974; Rowley and Halliwell, 
1982).  Other studies conducted by Montalescot et al. (1995) demonstrated that patients 
with restenosis showed elevations in several procoagulant factors such as PAI-1, tissue 
plasminogen activator antigen, fibrinogen, and factors VII and VIII.  In addition, 
Ishiwata et al. (1997) identified depression of the fibrinolytic response in patients who 
developed restenosis post-PCI as compared to those patients who did not develop 
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restenosis.  Homocysteine directly mediates the inhibition of fibrinolysis by preventing 
the cofactor activity of thrombomodulin and protein-C stimulation on endothelial cells 
(Hayashi et al. 1992; Rodgers and Conn, 1990; Lenz and Sadler, 1991).  In addition, 
homocysteine activates factor V activity, blocks anti thrombin III and inhibits t-PA 
binding to human endothelial cells (Rodgers and Kane, 1986; Nishinaga et al. 1993; 
Hajjar, 1993).  Unfortunately, procoagulant or fibrinolytic substances were not measured 
in the present study. It is possible however, that an association of post-PCI levels of 
homocysteine with restenosis is due to its procoagulant properties. As such, studies have 
shown that post-PCI restenosis is correlated to an increase in procoagulant and 
depression of fibrinolytic activity (Welch et al. 1996; Misra, 1974; Rowley and 
Halliwell, 1982; Ishiwata et al. 1997).  
 Prasad et al. (1994) have demonstrated the attenuation of the genesis of 
cholesterol diet-induced atherosclerosis in rabbits treated with the antioxidant probucol. 
Restenosis, after successful PCI, has been hypothesized to occur because of an 
aggressive healing process with increased intimal proliferation (hyperplasia), 
inflammation, thrombus formation and compression of the arterial wall (Beatt et al. 
1992; Lam et al. 1986; Liu et al. 1989).  Compression of the arterial wall by PCI devices 
causes destruction of the vasa vasorum in the arterial adventitia possibly causing arterial 
wall hypoxia, increased platelet activation and deep arterial wall injury (Lam et al. 
1986).  Animal model studies have revealed that the extent of post-stenting neointimal 
proliferation and restenosis is directly related to the extent of procedural coronary 
arterial injury (Frimerman et al. 1997; Carter et al. 1996).  Similarly, increased intimal 
hyperplasia from deep arterial injury (medial or adventitial) was reported in a post 
mortem study of patients who had post-PCI restenosis (Nobuyoshi et al. 1991).  Tardif et 
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al. (1997) reported from their Multivitamins and Probucol Trial (MVP) that the 
antioxidant probucol attenuates neointimal proliferation.  In their study, one month 
before PCI, 317 patients were randomly assigned to be administered twice a day either 
placebo, probucol (500mg), multivitamins (30,000 IU of beta carotene, 500mg of 
vitamin C, and 700 IU of vitamin E) or both probucol and multivitamins.  The results of 
their study showed that the restenosis was 40.3%, 38.9%, 28.9%, 20.7% respectively.  
Moreover, Prasad (1994) described the effectiveness of probucol in attenuating 
hypercholesterolemic atherosclerosis.  Moreover, Wantanabe et al. (1996) described the 
preventative effects of probucol on post-PCI restenosis.  In addition, Martin et al. (1997) 
reported that Vitamin E inhibits low-density-lipoprotein-induced adhesion of monocytes 
to human aortic endothelial cells in-vitro. Recently, Tardif et al. (2003) demonstrated 
that AGI-1067, a metabolically stable analog of probucol, has an equal antioxidant effect 
and attenuate restenosis following PCI.    The results of the present study indicate that 
patients who developed post-PCI restenosis had higher levels of oxidative stress (MDA) 
as compared to their pre-procedural values.  This suggests that post-PCI restenosis is 
associated with increased levels of ORs, which may be due to increased OR production 
and or decreased antioxidant reserve. 
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 5.0 CONCLUSION 
 The results of the present study suggest that (i) The pre-procedural levels of 
plasma homocysteine are not predictors of coronary restenosis.  However, the 6-month 
post-PCI levels of plasma homocysteine are associated with restenosis.  The values of 
plasma homocysteine increased by 24% at six-months as compared to the pre-procedural 
levels.  (ii) The pre-procedural concentrations of serum malondialdehyde are not 
predictors of post-PCI restenosis.  However, the 6-month post-PCI levels of MDA are 
predictors of post-PCI restenosis.  The values of serum MDA increased 109% at the six-
months post-PCI in those patients who developed restenosis as compared to the pre-
procedural levels (iii) The 6-month post-PCI levels of serum MDA are better predictors 
of restenosis than the post-PCI plasma levels of homocysteine (iv) There is a positive 
correlation between the pre-procedural levels of serum total cholesterol and LDL-C and 
post-PCI restenosis and (v) The pre-procedural concentration of HDL-C is negatively 
correlated with post-PCI restenosis. 
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